Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 1 of 72 
  
 
 
CLINICAL PROTOCOL  
 
PHASE 2 DOUBLE -MASKED, PLACEBO- CONTROLLED STUDY TO ASSESS THE SAFETY AND 
EFFICACY OF SUBCUTANEOUS LY ADMINISTERED  AKB -9778 15MG ONCE DAILY OR 15MG TWICE 
DAILY FOR 12 MONTHS IN PATIENTS WITH MODERATE TO SEVERE NON- PROLIFERATIVE 
DIABETIC RETINOPATHY  
 
 
Compound:  AKB -9778  
US IND Number:  113,322  
Protocol Number:  AKB -9778 -CI-5001  
Phase:  Phase 2 
Date:  Final Version        16 Sept 2016  
Amendment #1     01 Dec 2016 
Amendment #2     05 Jan 2017 Amendment #3     06 March 2017 Amendment #4     11 April 2017 
Amendment #5   18 Sept 2017  
  
Sponsor : Aerpio  Therapeutics LLC  
9987 Carver Road Suite 420 
Cincinnati, OH 45242  
 
This document contains information that is confidential and proprietary to the Sponsor , Aerpio  Therapeutics  
LLC .  This information is being provided to you solely for the purpose of evaluating and/or conducting a clinical 
trial for the Sponsor .  You may di sclose the contents of this document only to study personnel under your 
supervision, the Institutional Review Board, the United States Food and Drug Administration, or duly authorized 
representatives of regulatory agencies for this purpose under the condit ion that they maintain confidentiality.  The 
contents of this document may not be used in any other clinical trial, disclosed to any other person or entity, 
and/or published without the prior written permission of the Sponsor .  The foregoing shall not appl y to disclosure 
required by any regulations; however, you will give prompt notice to the Sponsor  of any such disclosure.  

Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 2 of 72 
 1 STUDY CONTACTS  
 
For study related and administrative questions, please contact:  
Laura Gambino , BS 
Director, Project Management 
Aerpio  Therapeutics  LLC  
9987 Carver Road, Suite 420 Cincinnati, OH  45242 Mobile Telephone:  (513) 253-9411 Email:  lgambino@aerpio.com  
 
For clinical and subject  related issues or questions, please contact:  
Barbara With ers, PhD  
Senior Director , Clinical Operations  
Aerpio  Therapeutics  LLC  
9987 Carver Road, Suite 420 
Cincinnati, OH  45242 
Mobile Telephone:  (513 ) 256-3592 
Email:  bwithers@ aerpio .com 
 Steve Pakola, MD Chief Medical Officer  
Aerpio Therapeutics  LLC  
9987 Carver Road, Suite 420 Cincinnati, OH  45242 Mobile Telephone:  (914 ) 309-3406 
Email:  spakola @aerpio.com  
 Mitchell Brigell, PhD  
Vice President , Clinical Development 
Aerpio Therapeutics  LLC  
9987 Carver Road, Suite 420 Cincinnati, OH  45242 Mobile Telephone:  (513) 432-7790 Email:  mbrigell@aerpio.com    
  
Protocol No. AKB-9778-CI-5001 
Amendment #5 Integrated 
1.1 Protocol Approval 
itchell Brigell, hD Date 
Vice President, Clinical Development 
Aerpio Therapeutics LLC 
~{J!1vt 
Barbara Withers, PhD 
Senior Director, Clinical Operations 
Aerpio Therapeutics LLC Steve ola, MD 
Chief Medical Officer 
Aerpio Ther euti LLC 
Aerpio -Company Confidential 
Page 3 of72 I 8 September20 I 7 
Date 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 4 of 72 
 1.2 Investigator Agreement 
I confirm that I have read and that I understand this protocol, the Investigator Brochure , and other 
product information provided by the Sponsor . I agree to conduct this study in accordance with the 
requirements of this protocol and also protect the rights, safety, privacy, and well -being of study 
subjects in accordance with the following: 
• The ethical principles that have their origin in the Declaration of Helsinki.  
• International Conference on Harmonization  Guidance for Industry, Good Clinical Practice 
E6. 
• All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations. 
• Regulatory requirements for reporting serious adverse events defined in this protocol. 
• Terms outlined in the Clinical Trial  Agreement.  
 
  
Signature of Investigator  Date  
  
Investigator  Name (print or type)   
  
Investigator’s  Title   
  
Name of Facility   
  
Location of Facility (City, State)   
  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 5 of 72 
 TABLE OF CONTENTS   
1 STUDY CONTACTS  ................................................................................................... 2  
1.1 Protocol Approval .................................................................................................... 3  
1.2 Investigator Agreement  ............................................................................................ 4  
2 PROTOCOL SUMMARY ............................................................................................ 9  
3 LIST OF ABBREVIATION S ..................................................................................... 13  
4 BACKGROUND INFORMATI ON ........................................................................... 16  
4.1 Rationale  ................................................................................................................. 17  
4.2 Summary of Nonclinical Experience  ..................................................................... 18  
4.3 Summary of AKB-9778 Clinical Experience ......................................................... 20  
4.4 Potential Benefits and Ris ks ................................................................................... 22  
4.4.1  Potential Benefits and Risks of AKB-9778 ....................................................... 22  
5 STUDY OBJECTIVES AND ENDPOINTS  .............................................................. 24  
5.1 Primary Objective  .................................................................................................. 24  
5.2 Secondary Objective  .............................................................................................. 24  
5.3 Exploratory Objectives ........................................................................................... 24  
5.4 Exploratory Efficacy Sub-Study Objectives (To be conducted at a subset of sites)24  
5.5 Primary Efficacy Endpoints ................................................................................... 25  
5.6 Secondary Efficacy Endpoints ............................................................................... 25  
5.6.1  Exploratory Efficacy Endpoints: ....................................................................... 25  
5.6.2  Exploratory Efficacy Sub-Study Endpoints ...................................................... 25  
5.6.3  Safety Endpoints:  ............................................................................................... 25  
6 STUDY DESIGN  ........................................................................................................ 26  
6.1 Study Design  .......................................................................................................... 26  
6.2 Rationale for Study Design  .................................................................................... 28  
6.3 AKB -9778 Dose Justification ................................................................................ 28  
6.4 Oversight of Safety  ................................................................................................. 28  
7 SELECTION AND WITHDRAWAL OF SUBJECTS  .............................................. 28  
7.1 General Criteria  ...................................................................................................... 28  
7.2 Subject Eligibility Criteria  ..................................................................................... 29  
7.2.1  Subject -Level Inclusion Criteria  ........................................................................ 29  
7.2.2  Subject -Level Exclusion Criteria: ..................................................................... 29  
7.3 Ocular Eligibility Criteria  ....................................................................................... 31  
7.3.1  Study Eye / Qualified Fellow Eye Inclusion Criteria: ....................................... 31  
7.3.2  Study Eye /Qualified Fellow Eye Exclusion Criteria  ........................................ 31  
7.4 Waivers  ................................................................................................................... 32  
7.5 Replacement of Subjects  ........................................................................................ 32  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 6 of 72 
 7.6 Discontinuation of Study Medication/Withdrawal of Subjects .............................. 32  
8 STUDY PRODUCT AND TR EATMENT OF SUBJECTS  ....................................... 33  
8.1 Study Medication, Supplies and Storage ................................................................ 33  
8.1.1  Storage and Handling of Study Medication ...................................................... 34  
8.2 Dispensing Procedures ........................................................................................... 34  
8.3 Treatment of Subjects  ............................................................................................. 34  
8.3.1  Treatment Group Assignments  .......................................................................... 34  
8.3.2  Randomization and Allocation to Treatment Group ......................................... 34  
8.3.3  Masking in the Study ......................................................................................... 35  
8.3.4  Unmasking ......................................................................................................... 35  
8.3.5  Study Drug Administration  ............................................................................... 35  
8.4 Prior and Concomitant Therapy ............................................................................. 36  
8.4.1  General  .............................................................................................................. 36  
8.4.2  Investigational Medications ............................................................................... 36  
8.4.3  Treatment of PDR or DME  ............................................................................... 37  
8.5 Product Accountability and Destruction ................................................................ 37  
9 STUDY PROCEDURES AND SCHEDULE OF ACTIVITI ES ................................ 38  
9.1 Administrative Procedures ..................................................................................... 39  
9.1.1  Informed Consent Procedure ............................................................................. 39  
9.1.2  Documentation of Screen Failures  .................................................................... 39  
9.1.3  Contraception and Pregnancy Avoidance Measures ......................................... 39  
9.1.4  Diet, Fluid and Activity Control ........................................................................ 40  
9.1.5  Laboratory Accreditation and Reference Ranges  .............................................. 40  
9.2 Study Procedures and Evaluations ......................................................................... 40  
9.2.1  Clinical Evaluations  ........................................................................................... 41  
9.2.2  Laboratory Evaluations: .................................................................................... 43  
9.3 Schedule of Activities  ............................................................................................ 45  
9.3.1  Visit Windows  ................................................................................................... 46  
9.3.2  Activities to be conducted at the Study Site  ...................................................... 46  
9.3.3  Activities to be conducted at the Homecare nurse visit .................................... 53  
10 ADVERSE EVENTS  .................................................................................................. 54  
10.1  Definitions  .............................................................................................................. 54  
10.1.1  Adverse Events (AEs)  ....................................................................................... 54  
10.1.2  Serious Adverse Events (SAEs) ........................................................................ 55  
10.1.3  Severity  .............................................................................................................. 56  
10.2  Eliciting Adverse Event Information  ..................................................................... 56  
10.3  Reporting ................................................................................................................ 56  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 7 of 72 
 10.3.1  Reporting Period ................................................................................................ 56  
10.3.2  Reporting AEs ................................................................................................... 56  
10.3.3  Reporting SAEs ................................................................................................. 57  
10.3.4  Relationship to Study Medication  ..................................................................... 57  
10.3.5  Follow-Up of Unresolved Events ...................................................................... 58  
10.4  Exposure In Utero  .................................................................................................. 58  
11 DATA ANALYSIS  ..................................................................................................... 59  
11.1  Sample Size Determination  .................................................................................... 59  
11.2  Study Populations ................................................................................................... 59  
11.2.1  Safety Populations ............................................................................................. 59  
11.2.2  Efficacy Populations .......................................................................................... 59  
11.3  Analysis of Demographics and Baseline Variables  ............................................... 59  
11.4  Disposition of Subjects ........................................................................................... 60  
11.5  Study Days and Assessment Windows .................................................................. 60  
11.6  Safety Analysis  ....................................................................................................... 60  
11.7  Efficacy Analyses  ................................................................................................... 60  
11.8  Pharmacokinetic Analyses  ..................................................................................... 61  
11.9  Pharmacodynamic Analyses  .................................................................................. 61  
11.10  Exploratory Genetic Analyses  ................................................................................ 61  
12 DATA HANDLING AND RECORD KEEPING  ...................................................... 61  
12.1  Case Report Forms (CRFs)  .................................................................................... 61  
12.2  Record Retention  .................................................................................................... 62  
13 QUALITY CONTROL (QC)  AND QUALITY ASSURANCE (QA)  ....................... 62  
13.1  Study Site Monitoring Visits  .................................................................................. 62  
13.2  Protocol Deviations ................................................................................................ 63  
14 TRIAL DISCONTINUATIO N/INVESTIGATIVE SITE  TERMINATION  ............. 63  
14.1  Criteria for Premature Termination or Suspension of the Study ............................ 63  
14.2  Criteria for Premature Termination or Suspension of Investigational Sites .......... 63  
14.3  Procedures for Premature Termination or Suspension of the Study or 
Investigational Site(s)  ............................................................................................. 63  
15 ETHICS  ....................................................................................................................... 64  
15.1  Ethical Conduct of the Study ................................................................................. 64  
15.2  Institutional Review Board (IRB) .......................................................................... 64  
15.3  Subject Information and Consent  ........................................................................... 64  
15.4  Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP .... 64  
15.5  Subject Confidentiality  ........................................................................................... 65  
16 PUBLICATION OF STUDY RESULTS  ................................................................... 65  
17 REFERENCES  ............................................................................................................ 66  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 8 of 72 
 18 APPENDICES  ............................................................................................................ 68  
18.1  Appendix A: Schedule of Activities  ....................................................................... 68  
18.2  Appendix B: Criteria for Treatment of PDR or DME in the Study Eye or Qualified 
Fellow Eye Durin g the Study ................................................................................. 71  
 
 
  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 9 of 72 
 2 PROTOCOL SUMMARY  
Protocol Number:   AKB -9778- CI-5001   
Protocol Title:  Phase 2 Double -masked, Placebo -Controlled Study To Assess The Safety And Efficacy Of 
Subcutaneously Administered AKB -9778 15mg Once Daily O r 15mg Twice Daily  For 12 Months In Patients With 
Moderate To Severe Non -Proliferative Diabetic Retinopathy  
 
 
Study Objectives:  Primary Objective:   
1. To assess the effects of AKB -9778 15mg once daily or 15mg twice daily for 12 months 
on severity of diabetic retinopathy in subjects with moderate to severe non -proliferative 
diabetic retinopathy  (NPDR)  
Secondary Objective:  
1. To assess the safety and tolerability of AKB -9778 15mg once daily or 15mg twice daily 
for 12 months in subjects with moderate to severe NPDR   
2. To determine the AKB -9778 systemic exposure based on sparse PK sampling in subjects 
with NPDR  
 
Exploratory Objectives:  
1. To explore the potential benefit of AKB -9778 on renal function  in subjects with NPDR  
2. To explore  the relationship between AKB -9778 systemic exposure and efficacy and 
safety  in subjects with NPDR  
 
Exploratory Efficacy Sub Study Objectives (To be conducted at a subset of sites)  
1. To explore the effects of AKB -9778 on optical coherence tomography angiography 
(OCT -A) in subjects with NPDR  
2. To explore the effects of AKB -9778 on retinal function as measured by 
electroretinogram (ERG) assessment in subjects with NPDR  
3. To explore the effects of AKB -9778 on peripheral retinal abnormalities  using ultra -wide 
field (UWF) fundus photography and UWF fluorescein angiography  
 
Study Endpoints: Primary Efficacy Endpoint  
1. Percentage of subjects with an improvement in study eye severity of diabetic retinopathy 
(DR) (Early Treatment Diabetic Retinopathy Study (ETDRS)  DR Severity Score or 
DRSS)  of ≥ 2 steps at Month 12 
Secondary Efficacy Endpoints  
1. Mean change from baseline in  DRSS  in the study eye  at Month 12   
2. Patient level (b inocular ) change from baseline in DRSS  (according to methods of Klein 
et al, 2001)  at Month 12  
3. Proportion of subjects with a worsening in the study eye DRSS of ≥ 2 steps at Month 12   
4. Proportion of subjec ts with an improvement or worsening in  the study eye DRSS of ≥ 3 
steps at Month 12   
5. Proportion of patients developing center -involved DME or PDR or PDR -related 
outcomes  during study  
6. Primary and secondary endpoints (1 through 4) assessed at Months 3, 6 and 9 
7. Primary and secondary assessments in all fellow eyes , fellow eyes that meet all 
eligibility criteria  (qualified fellow eyes) , and either  eyes (i.e. best response)   
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 10 of 72 
 Exploratory Efficacy Endpoints : 
1. Change from baseline in urine -albumin- to-creatinine ratio  (UACR)  and estimated 
glomerular filtration rate ( eGFR ) at Month 12  
Exploratory Efficacy Sub-S tudy Endpoints:  
1. Mean change from baseline in ERG parameters  at Month 12  
2. Mean change from baseline in indices of macular perfusion, as measured by OCT -A, at 
Month 12 
3. Mean change from baseline in area of peripheral non -perfusion, peripheral leakage, and 
peripheral retinopathy using UWF imaging, at Month 12 
Safety Endpoints:    
1. Incidence and severity of systemic and ocular adverse events (AEs)  
2. Change from baseline in body system assessments  
3. Change from baseline in vital sign measurements  
4. Change from baseline in ECG parameters  
5. Change from baseline in clinical laboratory assay results (blood chemistry , hematology , 
fecal occult blood  and urinalysis)  
6. Change from baseline in intraocular pressure (IOP)  
7. Change from baseline in slit lamp examination parameters  
8. Change from baseline in dilated funduscopic examination parameters  
9. Change from baseline in fluorescein angiogram (FA) parameters  
10. Mean change from baseline in ETDRS Best Corrected Visual Acuity (BCVA) letter 
score in the study eye at Month 12  
11. Proportion  of subjects  with a decrease of ≥15 letters in ETDRS BCVA at Month 12  
(compared to baseline)   
 
Study 
Population:  Subje cts with moderate to  severe NPDR (ETDRS Level 43 – 53 inclusive) , 18 through  80 
years  of age  (inclusive ), no evidence of central involved DME and ETDRS BCVA letter 
score ≥ 70 (Snellen 20/40 or better).   
Study Design:  Phase 2 randomized, double -masked,  placebo controlled, multi -center study, to evaluate the 
safety and efficacy of 12 month s of subcutaneous AKB -9778 administered either 15 mg QD 
or 15 mg BID in subjects with moderate to severe NPDR . Pharmacokinetic assessments  are 
included as an exploratory endpoint . Exploratory efficacy assessments (OCT -A, UWF 
imaging  and non -invasive ERG) will also be included at a subset of sites.   Blood samples  will 
be retained for biomarker and genetic analysis.    
General 
Statistical Methods and 
Types of Analyses:  Analysis Populations  
Safety Population  
The safety population will include all enrolled subjects who receive at least one dose of study 
medication. All safety analyses will be conducted using the safety population.  
Modified Intent -to-Treat Population  
The modified intent -to-treat (MITT) population will include all enrolled subjects who receive 
at least one dose of study  medication . The primary  efficacy analys is will be conducted using 
the MITT population.  
 
Per Protocol Population  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 11 of 72 
 The per protocol (PP) population will consist of all subjects in the MITT population who do 
not have major protocol deviations considered to affect the  primary efficacy variable DRSS, 
have completed a minimum of 12 month s of treatment  and have b een at least 70% compliant. 
Sensitivity analyses of the primary efficacy variables will be conducted using the PP 
population.  
Sample Size  
Estimates for sample size calculations are derived from published data from the analysis of the effect of ranibizumab (Lucentis®) and aflibercept (Eylea®) intravitreal administration 
regimens on DR severity score in the RISE/RIDE studies and VIVID/VISTA studies, 
respectively, in which 28-46% of subjects improved by ≥ 2 steps after 12 months of 
treatment.    
With 45 evalua ble subjects per treatment group, the study has > 85% power (based on 
Fisher’s Exact Test and a 2 -sided alpha =0.05 ) to demonstrate a statistically significant 
improvement in p roportion  of subjects improving by ≥ 2 steps on the ETDRS severity scale, 
assuming underlying rates for active and placebo of 30% and 5%, respectively. Assuming 
10% drop- out/non -evaluable rate, a sample size of 50 subjects per treatment arm 
(approximately 150 total) has been selected.  
Efficacy Analyses  
All efficacy data will be summarized by treatment group and time point using appropriate 
descriptive statistics. Summaries will be presented for both the MITT and PP populations.  The primary hypotheses to be tested is that AKB -9778 15mg twice daily and AKB -9778 
15mg once daily will be superior to placebo in the improvement of DR as measured by the ETDRS severity scale change from baseline at 12 months.  The primary hypotheses will be 
tested in the MITT population using a Fisher’s  Exact Test with a 2 -sided 5% significance 
level. To adjust for multiplicity, a pre -specified testing order will be used. AKB -9778 15mg 
twice daily will be tested first, and AKB -9778 15mg once daily will be tested second.  
Secondary and exploratory endpoin ts will be analyzed without adjustment for multiplicity.  
Continuous variables will be analyzed using ANCOVA models and dichotomous variables will be analyzed using the same approach as outlined for the primary endpoint.  Additional 
exploratory analyses wi ll be conducted to understand the relationship between exposure and 
response . 
Interim Safety Analys es 
On an ongoing basis throughout the conduct of the study, multiple layers of planned safety 
monitoring will be conducted. These include weekly masked reviews by the Aerpio Medical 
Monitor, monthly masked reviews by the Aerpio Clinical Safety Review Team (CSRT ), and 
quarterly masked reviews by the Safety Assessment Committee These review s are detailed in 
a separate document  (AKB -9778 Safety Surveillance Plan). 
Study Medication:  Subcutaneous treatments:  
• 15 mg AKB -9778 (in 100 mg/mL  Hydroxypropyl -Beta-Cyclodextrin [HPβCD] ) 
subcutaneous injection: To be provided as sterile pre -filled ready -to-inject syringes  
• Placebo  (Phosphate -Buffered Saline ) subcutaneous injection: To be provided as 
sterile pre -filled ready -to-inject syringes  
Duration of Treatment:  48 weeks   
Duration of Participation:  Screening period: up to 4 weeks ; Baseline and Treatment  period:  48 weeks ; Post -treatment 
Follow -up period: 4 weeks . The Screening, Baseline, Treatment , and Follow -up periods  will 
require subject participation for approximately 56 weeks . 
Number of Subjects:  Approximately 150 subjects ( 50 per treatment group)  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 12 of 72 
 Number of 
Study Centers:  Approximately 50 sites  
Volume of 
Blood Drawn:  Hematology ( 8 X 4 mL) 
Chemistry ( 14 X 3.5 mL) 
Serum Pregnancy ( 1 X 2.5 mL) 
Pharmacokinetic Samples ( 4 X 6 mL) 
Exploratory Biomarker (2 X 3  mL) 
Genetic Sample (1 X 8.5 mL) 
Total volume blood drawn for entire study: Approximately 134 mL per subject.   
  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 13 of 72 
 3 LIST OF ABBREVIATION S 
 
ADA  American Diabetes Association  
AE Adverse event  
ALT  Alanine transaminase (SGPT)  
Ang1  Angiopoietin 1 
Ang2  Angiopoietin 2 
AST  Aspartate transaminase (SGOT)  
AUC  Area under the curve  
BA Benzyl alcohol 
BCVA Best corrected visual acuity  
BID Twice daily  
BMI  Body mass index 
BP Blood pressure 
BUN  Blood urea nitrogen 
CBC Complete blood count 
Cmax  Maximum plasma drug concentration  
CPK Creatine phosphokinase 
CRF  Case report form  
CSRT  Clinical Safety Review Team  
CST Central Subfield Thickness  
CYP  Cytochrome 
CV Cardiovascular  
dL deciliter 
DME  Diabetic macular edema 
DR Diabetic retinopathy 
DRSS  Diabetic retinopathy severity score 
ECG  Electrocardiogram  
eCRF  Electronic case report form  
eGFR  Estimated glomerular filtration rate  
ETDRS  Early Treatment Diabetic Retinopathy Study 
ENT  Ears, nose and throat  
eNOS  Endothelial nitric oxide synthase 
EOT  End of treatment  
ERG  Electroretinogram  
FA Fluorescein angiograms 
FDA Food and Drug Administration 
FOBT  Fecal Occult Blood Test  
g gram  
GCP  Good Clinical Practice  
GI Gastrointestinal  
GLP  Good Laboratory Practice  
HbA1C  Hemoglobin A1c 
HEENT  Head, ears, eyes, nose and throat 
Hgb Hemoglobin 
HPβCD Hydroxypropyl Beta Cyclodextrin 
HPTPβ  Human Protein Tyrosine Phosphatase β 
HR Heart Rate  
ICH International Conference on Harmonisation  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 14 of 72 
 IND Investigationa l New Drug  
IOP Intra -ocular pressure  
IRB Institutional Review Board  
IRMA  Intra -retinal microvascular abnormalities  
IVT Intravitreal  
IWRS  Interactive web response system  
kg kilogram  
LC-MS/MS  Liquid chromatography- tandem mass spectrometry  
LDH Lactate dehydrogenase 
LFTs  Liver function tests  
MAD Multiple -ascending dose  
MCH Mean corpuscular hemoglobin  
MCHC  Mean corpuscular hemoglobin concentration 
MCV Mean corpuscular ( cell) volume 
MedDRA  Medical Dictionary for Regulatory Activities  
µL microliter  
µm micrometer 
mg milligram  
mL milliliter  
ms millisecond  
MITT  Modified intent- to-treat 
MTD  Maximum tolerated dose 
MPV  Mean platelet volume  
MDRD  Modification of Diet in Renal Disease  
NF National Formulary  
NPDR  Non-proliferative diabetic retinopathy 
NVE  Neovascularizati on elsewhere  
OCT  Optical coherence tomography 
OCT -A Optical coherence tomography angiography 
PBS Phosphate-B uffered -Saline  
PD Pharmacodynamic 
PDR  Proliferative Diabetic Retinopathy  
PK Pharmacokinetic  
POC  Proof of Concept  
PP Per protocol  
PRN as needed  
PRP Panretinal scatter photocoagulation  
QA Quality Assurance  
QC Quality Control 
QD Once daily 
RBC Red blood cell 
RDW  Red cell distribution width  
RVO Retinal vein occlusion  
SAC  Safety Assessment Committee  
SAD Single ascending dose 
SAE  Serious adverse event   
SC Subcutaneous 
SD Standard deviation 
SD OCT  Spectral domain optical coherence tomography  
SDH Sorbitol dehydrogenase 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 15 of 72 
 SHR  spontaneously hypertensive rats 
SSP Safety Surveillance Plan  
TEAE  Treatment emergent adverse event  
TIBC  Total Iron Binding Capacity 
Tie2 Tyrosine kinase with immune globulin-like and EGF-like domains2 
Tmax  Time to Cmax  
TSAT  Trasnferrin Saturation  
t1/2 Half-life 
UACR  Urine -albumin- to-creatinine ratio  
ULN Upper limit of normal 
US United States  
USP United States Pharmacopeia 
UWF  Ultra -wide field 
VEGF  Vascular endothelial growth factor 
VE-PTP  Vascular endothelial -protein tyrosine phosphatase 
WHO World Health Organization 
WBC White blood cell  
WKY  Wistar -Kyoto   
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 16 of 72 
 4 BACKGROUND INFORMATI ON 
Diabetes is estimated to affect 8.3% of the adult population, 382 million people worldwide, and 
this number is expected to rise to 592 million people by 2035 ( Guariguata et al ., 2014) . Diabetic 
retinopathy (DR) is a frequent complication of diabetes that may result in blindness. The 
incidence of DR increases with duration of diabetes. The prevalence of DR in the diabetic population is approximately 33%, with approximately 10% having vision threatening conditions of macular edema or proliferative retinopathy ( Yau et al ., 2012). By 20 years after disease 
diagnosis, nearly 100% of type 1 diabetics and 60% of type 2 diabetics develop DR ( Fong et al ., 
2004a,b). In the Wisconsin Epidemiologic Study of Retinopathy, the 25- year cumulative rate of 
retinopathy progression in Type 1 diabetics was 83%, with 43% of this population progressing to proliferative retinopathy (Klein et al., 2008) and 29% progressing to macular edema (Klein et al., 
2009). Based on these data, it is clear that diabetic retinopathy will increase as a public health problem, with both aging of the US population and increasing prevalence of diabetes over time.  
The severity of DR has been standardized using the Early Treatment Diabetic Retinopathy Study (ETDRS ) grading of standard 7-field fundus photographs. There is extensive evidence to show 
that as DR severity increases, the likelihood of development of macular edema or high- risk 
proliferative diabetic retinopathy ( PDR ) increases ( Davis et al ., 1998; Klein et al ., 2001). Thus, 
early detection and treatment of DR would dramatically reduce both visual disability associated with diabetes as well as the impact of this visual loss on health economics.  
In pivotal trials of intravitreal anti- VEGF  (vascular endothelial growth factor) effects on diabetic 
macular edema ( DME ), it was observed that treatment also had beneficial effects on DR. After 1 
year of treatment with Eylea ®, 33.5% of subjects treated monthly and 28.4% of subjects treated 
bi-monthly improved by ≥ 2 steps on the ETDRS severity scale, compared to 10.9% in the laser treatment group ( Korobelnik et al., 2014).  Similarly, in the RISE and RIDE trials with 
Lucentis®, 46.9% of subjects treated with 0.3 mg monthly and 46.8% of subjects treated with 
0.5 mg monthly for 2 years had a ≥ 2 step improvement in DR, compared to 6.8% of subjects treated with sham injections ( Ip et al ., 2012
). There was also a decrease in the percent of subjects 
who worsened by ≥ 2 steps after 2 years of treatment (2.5%, 2.0%, and 12.4% in the 0.3 mg 
Lucentis, 0.5 mg Lucentis, and sham groups, respectively). On the basis of these data, Lucentis 
and Eylea have been approved  for the treatment of DR  in patients with DME . However, t he 
efficacy of anti -VEGF therapy for the treatment of DR in patients without center -involved DME 
is unproven. Two trials have recently been initiated to test the efficacy of Eylea in this 
population (the PANORAMA study - [STUDY_ID_REMOVED] sponsored by Regeneron; and Protocol W - 
[STUDY_ID_REMOVED] sponsored by DRCR.net). However, it is important to note that eyes with non-
proliferative diabetic retinopathy ( NPDR ) and no DME have little visual dysfunction and thus 
the burden of multiple binocular intravitreal anti- VEGF injections may be unacceptable in this 
population. The objective of the present study is to examine the efficacy of AKB -9778 
subcutaneous administration in the treatment of NPDR in patients without DME . 
AKB -9778 is a first- in-class molecule in development for the treatment of diabetic eye disease, 
including DME and DR. AKB -9778 is a small molecule Tie2 (tyrosine kinase with 
immunoglobulin-like and EGF-like domains 2) activator that works through inhibition of VE -
PTP (vascular endothelial-protein tyrosine phosphatase), otherwise known as HPTPβ (human protein tyrosine phosphatase β), enhancing Tie2 activation and signaling.  Tie2 is a receptor 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 17 of 72 
 tyrosine kinase that is expressed principally in vascular endothelial cells and serves as the 
receptor for the angiopoietin family of secreted polypeptides .  Over the last decade, the 
Tie2/angiopoietin pathway has been identified as a key modulator of endothelial function and vascular stability (Augustin et al., 2009; Milner et al., 2009; Brindle et al., 2006; Fiedler et al., 
2006; Peters et al., 2004).  Members of the angiopoietin family are ligands for Tie2; angiopoietin 
1 (Ang1) is an agonist and angiopoietin 2 (Ang2) functions as a context dependent antagonist.  The bulk of evidence indicates that Ang1/Tie2 signaling promotes normal vascular integrity.  Conversely, in settings where Ang2 is upregulated, as in patients with diabetic retinopathy, Tie2 signaling is blunted and the vasculature is destabilized promoting vascular leak and enabling pathologic angiogenesis.   
VE-PTP is an endothelial tyrosine phosphatase that dephosphorylates Tie2, further reducing Tie2 
signaling.  Inhibition of VE -PTP with AKB -9778 overrides Ang2 and restores Tie2 signaling. 
Importantly, AKB-9778- mediated Tie2 activation results in activation of the PI3 
kinase/Akt/endothelial nitric oxide synthase (eNOS) pathway, a critical pathway in maintaining 
endothelial function and vascular integrity. Thus, AKB-9778 promotes vascular stability through enhanced Tie2 activation resulting in improved endothelial function, reduced vascular lea k and 
inflammation, and resistance to pathologic angiogenesis.  
In multiple preclinical vascular disease models, vascular stabilizing effects of AKB -9778 
resulted in decreased vascular leak and/or suppression of pathologic neovascularization.  In 
models of retinopathy, AKB-9778 dramatically reduced VEGF- driven retinal edema and 
neovascularization and prevented retinal detachment ( Shen et al ., 2014).  The vascular stabilizing 
properties of AKB-9778 may be beneficial in the treatment and prevention of a broad range of 
retinal pathology including nonproliferative and proliferative diabetic retinopathy, diabetic macular edema, neovascular age -related macular degeneration, and retinal vein occlusion, for 
which current therapy is not optimal.  
4.1  Rationale 
Please see the AKB -9778 Investigator Brochure for additional discussion and information for 
the following section. 
AKB -9778 is a small molecule that inhibits VE -PTP. This inhibition selectively increases the 
phosphorylation of Tie2 and a ugments Ang -1 signaling pathways through Tie2 that lead to 
vascular stabilization  and protection against vascular leak and pathologic angiogenesis.  
Two clinical studies in subjects with DME have been performed with AKB-9778, evaluating 
respectively 1 month and 3 months of treatment ( Campochiaro et al ., 2015, 2016). AKB -9778 
was well tolerated in these studies with no safety issues identified. The completed TIME -2 Proof 
of Concept study ( Campochiaro, 2016) has shown that SC dosing of AKB-9778 15 mg twice 
daily ( BID) may be of value in the treatment of DME when used in conjunction with Standard of 
Care anti -VEGF therapy and that AKB-9778 monotherapy may be effective in the treatment of 
NPDR . 
In the present study, the efficacy of AKB -9778 will be further evaluated in subjects with 
moderate to severe NPDR and no center -involved macular edema.  
 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 18 of 72 
 4.2 Summary of Nonclinical Experience  
Please see the AKB -9778 Investigator Brochure for additional discussion and information for 
the following section. 
A comprehensive nonclinical program has been conducted with AKB-9778 including evaluation 
in multiple retinopathy models, safety pharmacology studies, pharmacokinetic ( PK) and 
metabolism studies, toxicology studies in rats , dogs, and monkeys, embryo- fetal development 
studies in rats and rabbits, and genotoxicity studies.  The nonclinical program conducted to  date 
supports evaluation of the intended 15 mg QD and BID AKB-9778 hydroxypropyl- beta-
cyclodextrin ( HPβCD) dose formulation regimens  for a duration of 12 months in the current 
clinical study .  Please see the AKB -9778 Investigator Brochure for additional information.  
AKB -9778 has excellent SC bioavailability and demonstrates linear, dose-dependent inc reases in 
exposure following SC administration in rats, dogs and monkeys.  
In the Good Laboratory Practices (GLP) nonclinical safety studies, AKB-9778 formulated as a 
solution in 10% HPβCD demonstrated an excellent safety profile and was well tolerated by SC administration in rats, dogs, and monkeys. The primary target tissues for AKB-9778 were identified as injection sites  and l iver in rat, dog and monkey; skin/subcutis (vascular) in dog and 
monkey; and gastrointestinal ( GI; vascular) in dog.  
In the 6-month rat study elevations in AST and ALT were correlated with microscopic observations of scattered, individual, minimally necrotic hepatocytes. Similar findings were observed in the shorter duration (28- and 91-day) rat studies. In dogs, adverse liver findings have only been observed in the 28-day toxicity study, at the high dose, and included one incidence of mild randomly distributed foci of mild necrosis, associated with centrilobular vacuolation; non-adverse findings included hepatocellular degeneration also associated with centrilobular vacuolation, and one incidence of mild, randomly distributed microgranulomas in the liver. 
In the dog 9-month study, reversible, non-adverse and minimal panlobular hypertrophy of the 
liver was observed in all dose groups without any associated changes in liver transaminases.  In 
the 28-day monkey study there was no test article- related mortality and no definitive test article -
related mortality in the 273 -day monkey study. In the 273-day study, one of the 16 monkeys at 
22.5 mg/kg (33 -fold the clinical exposure at 15 mg BID) was sacrificed on Day 109 with 
cholestatic liver injury and associated  anemia which developed over a minimum of several 
weeks . The initial inciting event leading to early termination was not clear based on  full 
evaluation of all available data and the relationship to test article is uncertain. The different 
characteristics of the liver responses in rat, dog, and monkey suggest different processes and/or 
pathogenesis for the liver effects in each species.  For guidance on assessment and monitoring of 
potential liver findings refer to the Investigator ’s Brochure.  
In rat, dog, and monkey, injection sites had findings related to the subcutaneous injection procedure (repeated injection of a limited number of injection sites on animals) with exacerbation by the presence of AKB -9778.  SC injections of AKB-9778 as a solution in these 
nonclinical studies were generally well tolerated by rats, dogs and monkeys with only sporadic or transient observation of injection si te redness, thickening, or  scabbing. These findings were 
correlated histopathologically with focal SC hemorrhage, inflammation, fibrosis, and necrosis that were observed to largely recover. In early clinical trials with the AKB -9778 HPβCD 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 19 of 72 
 formulation , few adverse effects at the injection site were reported for injection volumes of less 
than 1 mL and mild to moderate transient pain was reported for injection volumes of 1 mL or 
greater.  
In the 9-month dog toxicity study, broadly distributed dermal- localized n odules were observed 
on all dogs at 15 and 30 mg/kg/day and one nodule was observed on one male dog at 6 mg/kg/day. The majority of nodules were identified microscopically as focal angiectasis, characterized as ectatic, blood -filled vessels with varying de grees of thrombosis that was 
occasionally associated with papillary endothelial hyperplasia; and  one nodule in a high dose dog 
identified as benign hemangioma. The nodules ranged in size between 1 and 50 mm in diameter and appeared to slowly enlarge or rem ain static in size. The majority of nodules were persistent, 
but a few nodules were self -limiting while AKB -9778 dosing continued. The dermal nodules 
were observed to rapidly resolve upon drug withdrawal. In addition, largely GI tract- localized 
minimal to mild angiectasis was observed  by microscopic examination  at all dose levels in dog 
(at exposures 6 - to 24-fold the human exposure at 15 mg BID) and not present in the vehicle 
control group. The vascular findings were not associated with any clinical observ ations, serum 
chemistry, or other microscopic changes. In the rat 6 -month study, minimal focal angiectasis was 
observed by microscopic examination  in the uterus with cervix of one high- dose rat (at higher 
AUC exposure than exposures assessed in dog) and was considered incidental .  There were no 
skin nodules or GI-related findings in rat. In the 9 -month monkey study, a solitary dermal nodule 
on the tail of one high dose animal was characterized as angiectasis with resolving thrombosis, and associated with AUC exposure higher than exposures assessed in dog. There were no GI-related findings in monkey. These observations suggest an increased sensitivity  of the dog to 
vascular effects of AKB -9778. No unusual or unexpected dermal findings have been observed in 
clinical studies with AKB -9778. For guidance on assessment and monitoring of potential 
vascular effects refer to the Investigator’s Brochure.  
A consistent finding in both rat and dog was a non-adverse decrease in blood pressure. In normotensive Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR), blood pressure was decreased (the decrease in systolic pressure was greater than the decrease in diastolic pressure [systolic > diastolic]) with a compensatory increase in heart rate. Similarly, in the dog cardiovascular (CV) study, blood pressure was decreased (systolic > diastolic) with a compensatory increase in heart rate. Changes in blood pressure in both species were transient (4-6 hours), correlated with the drug plasma profile, and appeared to plateau with increasing dose, consistent with a pharmacological effect. As mentioned previously, activation of Tie2 results in endothelial nitric ox ide synthase (eNOS ) activation, which generates the potent vasodilator, 
nitric oxide ( NO). AKB -9778 activates Tie2 and eNOS in cultured vascular endothelial cells, 
which supports a pharmacologic basis for vasodilation and decreased blood pressure.  
Another consistent finding in dog was a non- adverse increase in cholesterol and triglycerides  
without microscopic correlate . These changes resolved during the recovery period and were not 
associated with microscopic changes . In early clinical trials with AKB -9778, no clinically 
meaningful changes in clinical chemistry (including total cholesterol and triglycerides) have 
been observed.  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 20 of 72 
 4.3 Summary of AKB-9778 Clinical Experience 
Please see the AKB -9778 Investigator Brochure for additional discussion and information for 
the following section. 
To date, AKB-9778 has been evaluated in six  completed early phase studies: a Phase 1a single 
ascending dose ( SAD) study ( AKB -9778- CI-2001) in healthy male volunteers, a Phase 1  
pharmacokinetic- pharmacodynamic crossover single dose study of an extended release 
suspension formulation ( AKB -9778- CI-3001), a 1-month Phase 1b multiple ascending dose 
(MAD) study in subjects with DME (AKB -9778- CI-2002 ), a 3-month Phase 2a POC study in 
subjects with DME (AKB -9778- CI-2003), a Phase 1  pharmacokinetic- pharmacodynamic 
crossover single dose study evaluating extended release solution and suspension formulations 
(AKB -9778- CI-3002); and a Phase 1 repeat -dose, PK/tolerability study evaluating exte nded 
release solution formulations ( AKB -9778- CI-3003 ). AKB -9778 is also being evaluated in two 
ongoing studies : a single -center, 3 -month Phase 2a POC study in subjects with retinal vein 
occlusion ( RVO) ( AKB -9778- CI-4001) and a Phase 1 ADME study (AKB-9778- CI-3004).  
The initial Phase 1a study, (Study AKB-9778- CI-2001) was a double-masked, placebo 
controlled, SAD study conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of 6 single ascending subcutaneous doses of AKB-9778 including one administered as a divided dose in healthy male volunteers. Six cohorts of eight subjects each were randomized to receive either AKB -9778 or placebo (6:2). AKB-9778 doses evaluated over 
a single day of dosing were 5, 10.5, 20, 40, or 80 mg administered as a single dose, or 120 mg [(administered as 2 doses, 60 mg each, separated by 12 hours (i.e. 60 mg BID)]. Exposure following single ascending doses of AKB-9778 was dose proportional with no evidence of accumulation when administered as 2 doses separated by 12 hours (60 mg BID). Absorption and elimination were rapid (T
max ~ 15 -30 minutes and T 1/2 ~ 1-2 hours). Single doses of AKB-9778 
through 40 mg were generally well tolerated. At doses of 60, 80, and 120 mg (60 mg BID), an increase in the type and frequency of systemic AEs consistent with the exaggerated vasodilatory pharmacology of AKB- 9778 was observed. These events were transient and generally resolved 
within 2 -8 hours post-dose. At doses ≥ 60 mg, orthostatic symptomology observed during a 
3-5 minute standing blood pressure (BP) assessment improved upon return of subjects to supine position, and resolved by 1-3 hours post-dose without treatment other than oral fluids. There were no severe or serious adverse events (SAEs) and no clinically significant changes or trends in safety laboratory tests, electrocardiogram (ECG) parameters, vital signs (except orthostatic 
BP), or physical exams in AKB -9778 or placebo treated subjects. 
Study AKB -9778- CI-2002, a Phase 1b, open-label, MAD cohort study, was conducted to assess 
the safety, tolerability, pilot efficacy, PK and pharmacodynamic ( PD) effects of 28 -day repeat 
subcutaneous doses of AKB-9778 in subjects with DME. Four dose cohorts were administered 5, 
15, 22.5 and 30 mg AKB -9778 BID, respectively. Twenty- six subjects in total were enrolled. 
Consistent with plasma exposure profiles in the healthy volunteer study, exposure in DME subjects increased with increasing dose levels of AKB -9778 with no evidence of significant 
accumulation. Absorption and eliminati on were rapid with an elimination half -life of 
approximately 1 hour. All AKB- 9778 doses were generally well tolerated. There were no SAEs. 
Adverse events, consistent with the exaggerated vasodilatory pharmacology of AKB-9778, emerged at AKB -9778 doses of 22.5 and 30 mg BID and included dizziness, headache, and 
presyncope/syncope. These events were transient, usually occurred within the first hour after 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 21 of 72 
 dosing, and generally resolved within 5 minutes to one hour after onset. There were no clinically 
meaningf ul abnormalities or changes from baseline in safety laboratory tests (chemistry, 
hematology, and urinalysis), ECG parameters, vital signs or physical exams. In the 22.5 and 30 mg BID dose groups, consistent modest decreases in resting systolic BP (with corresponding modest increases in heart rate (HR)) were observed following dosing (30 mg >22.5 mg). These effects were largely asymptomatic and transient, and the timing of the effects correlated with the rapid AKB-9778 absorption and elimination plasma conce ntration -time curve. Pilot efficacy 
evaluations, including assessments of retinal thickness and visual acuity, suggest that AKB-9778 exhibited biologic activity.  
AKB -9778- CI-2003 was a Phase 2 proof of concept ( POC ) study which further explored the 
efficac y of AKB -9778 in DME when administered for 3 months. In this trial, AKB-9778 was 
evaluated as monotherapy (subcutaneous administration of 15 mg BID), and in combination with ranibizumab intravitreal (IVT) injection. A ranibizumab active control group was a lso evaluated. 
AKB -9778 was well tolerated in subjects when administered BID either as monotherapy or as 
combination therapy with monthly ranibizumab IVT injection. There were no meaningful imbalances among treatment groups in either ocular or non- ocular treatment emergent adverse 
events (TEAEs), and no deaths or treatment- related SAEs were reported. Transient effects on 
baseline BP and HR following Day 1 dosing were observed, but the effects were not of clinical concern, and after 3 months (end of treatment), there were no differences in BP and HR between treatment groups. Hematology and blood chemistry did not yield clinically meaningful results for any treatment group, and clinically significant changes in physical examination, slit- lamp 
biomicroscopy parameters, intraocular pressure evaluations, and indirect dilated ophthalmoscopy evaluations were few and distributed similarly among treatment groups. When used in combination with ranibizumab, AKB- 9778 demonstrated a statistically significant improvement 
in the reduction of central subfield thickness ( CST) that also was statistically significantly 
greater than the improvement seen in the use of ranibizumab alone. Analysis of diabetic retinopathy severity score (DRSS) showed evidence that AKB -9778 monotherap y increased the 
percent of eyes that gain 2 or more steps in DRSS compared to placebo and had an effect on DRSS similar to ranibizumab ( Campochiaro et al., 2016).  
The previously described studies utilized an AKB-9778 formulation prepared using HPβCD as a solubilizing agent. A recently completed Phase 1 SAD study, AKB-9778- CI-3002, evaluated the 
safety, tolerability and bioavailability of an AKB-9778 solution formulation utilizing 1.5% benzyl alcohol (BA) as a solubiliz ing agent relative to AKB -9778 in 12.5% HPβCD.   
Study AKB -9778- CI-3002, conducted in healthy subjects, evaluated the single-dose PK, 
hemodynamic effects (BP and HR), and the safety and tolerability of two dose levels (15 and 30 mg) of AKB -9778 containing 1.5% BA relative to 15 mg AKB-9778 containing 12.5% HPβCD. 
All formulations and doses evaluated in the study were safe and well tolerated. Similar to the results of the previous clinical studies, all formulations and doses of AKB-9778 demonstrated a small,  transient reduction in BP and increase in HR within first hour after dosing.  
Study AKB -9778- CI-3003, conducted in healthy subjects, evaluated 7-day BID subcutaneous 
administration of three different formulations of AKB-9778. In this study a 1.5% BA formu lation was used to test 15 mg and 30 mg doses of AKB-9778, a 3.0% BA formulation was 
used to test 30 mg, 45 mg, and 60 mg AB-9778 doses, and a 12.5% HPβCD formulation was used to test 15 mg AKB-9778. Placebo injections of 1.5% BA and 3.0% BA were also tested. All 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 22 of 72 
 doses were given subcutaneously BID for 7 days (volume 0.75 ml). The trial was randomized 
and double-masked.  The 15 mg AKB-9778 in 12.5% HPβCD formulation was well tolerated both systemically and locally.  The AKB-9778 in BA formulations, while be ing well tolerated 
systemically, demonstrated injection site reactions (mild to moderate in intensity) in at least 2 subjects in each of the treatment arms.  Injection site reactions were also observed in the 3% BA vehicle arm.  Therefore, the current stud y will evaluate the AKB -9778 in an HPβCD 
formulation. 
The totality of the nonclinical and clinical data support continued clinical development of 
AKB -9778 as a treatment for DR.  The current clinical study, AKB -9778- CI-5001, is a Phase 2 
study which will e xplore the safety and efficacy of 15 mg AKB -9778 in the treatment of subjects 
with moderate to severe NPDR in the absence of center -involved DME when administered QD 
or BID for 12 months (48 weeks).      
4.4 Potential Benefits and Risks 
4.4.1  Potential Benefits and Risks of AKB-9778 
Please see the AKB -9778 Investigator Brochure for additional discussion and information for 
the following section. 
Collectively, the nonclinical pharmacology data in diverse models is consistent with the 
proposed mechanism whereby AKB-9778 inhibits VE-PTP resulting in Tie2 activation and 
improves endothelial function and vascular stabilization, supporting the potential efficacy of VE-PTP inhibition with AKB-9778 in a broad range of retinal pathology. The completed clinical 
Phase 2a study in subjects with DME shows that Tie -2 activation  via AKB -9778 enhances 
treatment of macular edema when combined with an anti -VEGF inhibitor and has evidence of 
efficacy as monotherapy in the treatment of NPDR .  
The safety of VE -PTP inhibition with AKB -9778 has been explored in nonclinical safety studies, 
in multiple nonclinical pharmacology studies and in seven clinical studies.   
Clinically, AKB -9778 has shown no evidence of significant safety issues to date. A transient, 
generally asymptomatic reduction in blood pressure is observed reflecting the vasodilatory pharmacodynamic effect of Tie-2 activation. At doses above the 15 mg dose used in the Phase 1b AKB -9778- CI-2002 study, vasovagal events (presyncope/syncope) have been observed 
following the first dose of AKB-9778. A vasovagal event was observed after the first dose in 1/144 (0.7%) subjects in the Phase 2 AKB -9778- CI-2003 study. This subject did not experience 
any such events during the subsequent 3 months of dosing. No other vasovagal events were observed in this study. In both studies there was a significant correlation between baseline BP 
and change in BP . Specifically, subjects with higher BP had greater reductions in BP. 
Based on nonclinical studies and clinical studies conducted to date, identified risks include transient injection site reactions, hepatotoxicity, hemodynamic effects, hematologic and plasma lipid effects, and vascular effects.   
In the nonclinical rat studies, findings of reversible  and acute, individual hepatocellular necrosis 
of minimal severity  were observed  that correlated with elevations in AST and ALT  in some 
animals.  In dogs, adverse liver findings have only been observed in the 28- day toxicity study, at 
the high dose, and included one incidence of mild randomly distributed foci of mild necrosis, 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 23 of 72 
 associated with centrilobular vacuolation; non- adverse findings included hepatocellular 
degeneration also ass ociated with centrilobular vacuolation, and one incidence of mild, randomly 
distributed microgranulomas in the liver . In the dog chronic 9-month study, reversible, non-
adverse and minimal panlobular hypertrophy of the liver was observed in all dose groups without 
any associated changes in liver transaminases. In the monkey chronic 9-month study, one of the 
16 monkeys at 22.5 mg/kg (33-fold the clinical exposure at 15 mg BID) was sacrificed on Day 109 with cholestatic liver injury and associated anemia which  developed over a minimum of 
several weeks. In prior AKB -9778 clinical trials, in subjects treated for 3 months with AKB-
9778 15mg BID, 0/113 had transaminase (ALT or AST) elevation >5X upper limit of normal (ULN) at any monthly assessment timepoint; 1/113  subjects (1/16 RVO patients; 0/97 DME 
patients) had a single occurrence of asymptomatic ALT elevation >3X but < 5X ULN at the end of treatment. This subject had an ALP slightly above ULN at pre-treatment and 2.05X ULN at the end of treatment, with all oth er labs (including AST, bilirubin and total protein) normal 
throughout the study. ALT and ALP levels were normal on repeat assessment 4 weeks later.  The rate of LFT findings observed to date in patients treated with AKB-9778 is in the range reported for p lacebo groups in clinical trials (Llanos et al, 2010), particularly given the absence of any 
cases associated with elevated bilirubin levels.   
In the subchronic (28-day) dog and monkey studies, decreases in hemoglobin and hematocrit were observed at the h igh doses with no microscopic correlate and were considered possibly 
associated with effects at the injection sites.   However, in the chronic rat, dog and monkey 
studies, except for the single monkey described above with cholestatic liver injury and associated 
anemia, decreases in hemoglobin or hematocrit were not observed. Non -adverse increases in 
cholesterol and triglycerides were observed in dogs in all pivotal studies with no associated microscopic changes. These changes resolved within the recovery per iods.  No significant 
hematologic or plasma lipid abnormalities were observed in the 9 -month monkey study. In all 
clinical trials with AKB -9778 to date, no clinically meaningful changes in hematological 
parameters (including hemoglobin and hematocrit) or plasma lipids (including total cholesterol and triglycerides) have been observed.   
Dermal  nodules, characterized microscopically as  angiectasis (dilated, blood filled vessels),  
have been observed in the chronic 9-month dog toxicity stud y and with a single incidence in one 
high-dose monkey in the chronic 9-month monkey study; however, no unusual dermal findings 
have been observed in human clinical studies of durations of up to 3 months. Whether ectasias will be seen when patients are dosed for longer periods is unknown. In the chronic dog study, angiectasis was  also identified microscopically largely in  the GI tract  after the 9 -month dosing 
period. These changes were asymptomatic (i.e. there was no bleeding, loss of appetite, or other 
observable clinical abnormalities of the GI tract)  at exposures up to 24-fold above the human 
clinical exposure.   
The current clinical study employs robust safety monitoring to assess for potential adverse effects.  Safety assessments in the current study include body system assessments , vital sign 
monitoring, clinical laboratory assessments (including blood chemistry, hematology, fecal occult blood testing, and urinalysis), vision and ocular assessments.   
On an ongoing basis throughout the conduct of the study, a variety of planned safety monitoring 
reviews of available study data will be conducted (as detailed in Section 6.4 Oversight of Safety 
and in the AKB -9778 Safety Surveillance Plan ).  These include weekly reviews conducted by the 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 24 of 72 
 Aerpio M edical Monitor, monthly masked reviews by the Aerpio Clinical Safety Review Team 
(CSRT), and quarterly masked reviews by the Safety Assessment Committee (SAC: composed 
of members independent of the clinical team including Aerpio physician/cardiologist, a non-sponsor independent physici an experienced in the assessment of clinical trial safety data, a non-
sponsor independent physician with expertise in gastrointestinal/hepatology safety assessment, and a non-sponsor independent physician/ophthalmologist with expertise in ophthalmology safety assessment ).    
Given the safety history of AKB-9778 and the robust safety monitoring implemented in this study, there is anticipated to be minimal risk of drug -related severe adverse effects as a result of 
participation in this study.  
In nonclinical  reproductive toxicology studies (rats and rabbits), AKB-9778 was not associated 
with embryo -fetal abnormalities.  Additionally, in the chronic repeated -dose rat (6-month) and 
dog (9 -month) toxicity studies, there was no evidence of reproductive organ toxic ity.  
Nonetheless, enrollment of women of child bearing potential and non- vasectomised male 
subjects will remain limited to subjects willing and able to use acceptable methods of contraception.  
5 STUDY OBJECTIVES AND ENDPOINTS  
5.1 Primary Objective 
1. To assess th e effects of AKB -9778 15 mg once daily or 15 mg twice daily for 12 months 
on severity of diabetic retinopathy in subjects with moderate to severe NPDR   
5.2 Secondary Objective 
1. To assess the safety and tolerability of AKB -9778 15 mg once daily or 15 mg twice daily  
for 12 months in subjects with moderate to severe NPDR   
2. To determine the AKB -9778 systemic exposure based on sparse PK sampling in subjects 
with NPDR  
5.3 Exploratory Objectives 
1. To explore the potential benefit of AKB-9778 on renal function in subjects wi th NPDR  
2. To explore the relationship between AKB -9778 systemic exposure and efficacy and safety  
in subjects with NPDR  
5.4 Exploratory Efficacy Sub -Study Objectives (To be conducted at a subset of 
sites) 
1. To explore the effects of AKB -9778 on optical coherence tomography angiography ( OCT -
A) in subjects with NPDR  
2. To explore the effects of AKB -9778 on retina function as measured by e lectroretinogram 
(ERG ) assessment in subjects with NPDR  
3. To explore the effects of AKB -9778 on peripheral retinal abnormalities  using ultra- wide 
field (UWF) fundus photography and UWF fluorescein angiography 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 25 of 72 
 5.5 Primary Efficacy Endpoints  
1. Percentage of subjects with an improvement in study eye severity of diabetic retinopathy  
(DR) (ETDRS DR Severity Score or DRSS) of ≥ 2 steps at Mon th 12   
5.6 Secondary Efficacy Endpoints  
1. Mean change from baseline in DRSS in the study eye at Month 12  
2. Patient level (b inocular ) change from baseline in DRSS (according to methods of Klein et 
al, 2001) at Month 12 
3. Proportion of subjects with a worsening in the study eye DRSS  of ≥ 2 steps at Month 12  
4. Proportion of subjects with an improvement or worsening in the study eye DRSS of ≥ 3 
steps at Month 12  
5. Proportion of patients developing center-involved DME or PDR or PDR -related outcomes 
event during study  
6. Primary and secondary endpoints (1 through 4) assessed at Months 3, 6 and 9 
7. Primary and secondary assessments in all fellow eyes , fellow eyes that meet all eligibility 
criteria  (qualified fellow eyes) , and either eye (i.e. best response) 
5.6.1 Exploratory Efficacy Endpoints:  
1. Change from baseline in urine- albumin -to-creatinine ratio (UACR) and estimated 
glomerular ( eGFR ) at Month 12 
5.6.2 Exploratory Efficacy Sub-Study Endpoints  
1. Mean change from baseline in ERG parameters  at Month 12 
2. Mean change from baseline in  indices of macular perfusion, as measured by OCT-A , at 
Month 12 
3. Mean change from baseline in area of peripheral nonperfusion, peripheral leakage, and 
peripheral retinopathy using UWF imaging, at Month 12 
5.6.3 Safety Endpoints: 
1. Incidence and severity of systemic and ocular AEs 
2. Change from baseline in body system assessments  
3. Change from baseline in vital sign measurements  
4. Change from baseline in ECG parameters  
5. Change from baseline in clinical laboratory assay results (blood chemis try, hematology, 
fecal occult blood, and urinalysis) 
6. Change from baseline in intraocular pressure (IOP) 
7. Change from baseline in slit lamp examination parameters  
8. Change from baseline in dilated funduscopic examination parameters 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 26 of 72 
 9. Change from baseline in fluorescein angiogram (FA) parameters  
10. Mean change from baseline in ETDRS best corrected visual acuity (BCVA) letter score in 
the study eye at Month 12  
11. Proportion of subjects with a loss of ≥15 letters in BCVA at Month 12 (compared to baseline)  
6 STUDY DESIGN  
6.1 Study Design 
This is a Phase 2 randomized, double-masked, placebo controlled, multi- center study, to evaluate 
the safety and efficacy of 12 months (48 weeks) of subcutaneous AKB-9778 administered 15 mg 
QD or 15 mg BID in subjects with moderate to severe NPDR. Exploratory evaluations include 
pharmacokinetic assessments, as well as exploratory efficacy assessments ( OCT -A, UWF 
imaging  and non- invasive ERG) at a subset of sites . Blood samples will be retained for 
biomarker and genetic analysis.    
 
Subjects wi ll participate in the study for approximately 56 weeks  (Screening period up to 4 
weeks , Baseline and Treatment periods for 4 8 weeks , and Follow-up period for 4 weeks ). 
The study will be conducted at approximately 50 investigative sites.   
Subjects will be randomized 1:1:1  to either AKB -9778 15mg QD, AKB -9778 15mg BID, or 
placebo treatment groups .  Fifty  (50) subjects are planned per group.  The treatment groups are 
as follows:  
• Active Group: SC AKB -9778 15 mg (QD); To maintain masking, subjects will receive 
BID dosing with masked study medication a dministered as one dose of active and one 
dose of matching placebo  
• Active Group: SC AKB -9778 15 mg ( BID)  
• Placebo Group: SC Phosphate-B uffered -Saline (P BS) (BID)  
Subjects will self -administer study medication as SC injections in the abdomen (preferably) 
around the same time every morning and evening, if possible (See Section 8.3.5).  The 
Investigator, all study -site personnel, Central Image Reading Center  personnel, and subjects will 
be masked to treatment assignment during the entirety of the study.  
For safety monitoring throughout the conduct of the study, o cular image data (fundus 
photographs, including red free images, fluorescein angiography, and OCT) for both the study 
and fellow eye will be read locally by the Investigator.   
All ocular image data will be transmitted to a Central Image Reading Center.  Modified 7- Field 
or 4-Wide Field color fundus photos will be graded for ETDRS DRSS by the Central Image 
Reading center.  The Central Image Reading center will confirm study eye eligibility based on 
ocular imaging criteria.  The Central Image Reading Center  will provide the Screening DRSS 
value to investigative sites which will be used for randomization stratification based on Screening photos (See Section 8.3.2).  Ocular images analyzed at the Central Image Reading 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 27 of 72 
 Center will be used for final statistical analyses.  Reading center personnel will be masked to 
subject treatment and the reading and grading will be done in a masked fashion. 
Randomization will be stratified by study eye screening ETDRS DRSS  (levels 43, 47 and 53 
equally distributed between the treatment groups). The number of study eyes with moderate 
severity of DR (level 43) will be limited to 50 .   
Spot UACR  and eGFR  will be assessed as exploratory assessments to evaluate for any potential 
effects on renal function . UACR will be evaluated at Baseline, Month 6, Month 9, and Month 12 
(EOT) . eGFR will be evaluated at Screening, Baseline , Month 6, Month 9, and Month 12 (EOT). 
Plasma samples will be collected at specified times on Day 1  and Month 6 visit for PK 
assessments.  These samples will be analyzed for AKB -9778 using validated bioanalytical 
methods. A blood sample will be retained for exploratory genetic analysis that may provide insight into the 
role of the VE -PTP/ Tie2 pathway in diabetic retinopathy and an individual subject's response to 
AKB -9778 treatment. Similarly, blood samples collected at baseline and Month 12 End of 
Treatment (EOT) will be retained for exploratory analysis of b iomarkers in plasma associated 
with VE -PTP inhibition and Tie2 activation.  Once results of the study are known, the Sponsor 
will determine the value of conducting the genetic and biomarker assessments.  
Subjects will be seen at the investigative site ever y 4 weeks while participating in the study.  At 
each monthly visit, subjects will undergo blood pressure and heart rate monitoring and visual acuity assessments. Subjects will also be questioned about any symptoms since their prior visit, and any adverse events and changes or additions to concomitant medications will be documented. Subjects will undergo blood sampling for clinical laboratory assessments (monthly for chemistry and every other month for hematology assessments). Fecal occult blood will be evaluated at  Screening , Month 6, Month 9, and Month 12 (EOT). Subjects will collect their stool 
specimens at home and ship directly to the central clinical laboratory for testing; Investigative 
sites will distribute instructions and supplies for specimen collection and shipping. Every three 
months, subjects will also undergo a battery of comprehensive ocular assessments at the investigative site including slit lamp biomicroscopy, IOP, dilated indirect ophthalmoscopy, SD-
OCT, fundus photography and fluorescein angiography (at Months 6 and 12 only). Exploratory efficacy assessments (OCT -A, UWF imaging and non-invasive ERG) will also be included at a 
subset of sites.    
In addition to the assessments at the study site visits, at Screening and every three months during 
the treatment period , subjects will be visited at their homes by a home healthcare nurse, who will 
conduct body system assessments  and review status of specimen collection f or fecal occult blood 
testing (on relevant visits) . The home health care nurse will also conduct the 1 month Follow- Up 
visit.  At this visit, the nurse will collect medical history and conduct a body system assessment.  
If the home healthcare nurse identif ies any potential AEs during the home visit, the nurse will 
communicate directly to the study site and the Investigator will be responsible for determination 
of AEs and any necessary follow -up with the subject. The home healthcare nurse visits are 
anticipa ted to provide an additional measure of safety oversight. 
The safety and tolerability of AKB -9778 will be determined by incidence and severity of 
treatment emergent AEs and changes from baseline in ECG, vital sign measurements , clinical 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 28 of 72 
 laboratory assay results (blood chemistry, hematology , fecal occult blood , and urinalysis ), 
BCVA, IOP, slit lamp examinations, funduscopic examinations and fluorescein angiograms 
(FA).  
6.2 Rationale for Study Design  
This Phase 2 study is being conducted to assess the safety and efficacy of AKB -9778 15 mg QD 
and AKB-9778 15 mg BID when administered daily for 12 months ( 48 weeks) in subjects with 
moderate to severe NPDR and no center -involved DME .     
6.3 AKB-9778 Dose Justification 
In two previous studies of AKB-9778 in subjects with DME, a 15 mg BID dose regimen using 
the HPβCD formulation has been well tolerated for up to 1 month and 3 months of treatment, respectively . The AKB -9778 dose regimen selected for this study is  anticipated to be well 
tolerated based on nonclinic al toxicology studies and clinical evaluation in humans and should 
allow for evaluation of efficacy without undue safety risk for participating subjects. Additionally, this dose regimen was associated with an increased percent of DME subjects achieving at least a 2-step improvement in DRSS compared to placebo. To evaluate if less frequent administration may also achieve efficacy, an AKB -9778 15 mg QD dose regimen arm is also included in this 
study.  
6.4 Oversight of Safety 
On an ongoing basis throughout the conduct of the study a variety of planned safety monitoring reviews of available study data will be conducted.  These include weekly reviews conducted by the Aerpio Medical Monitor, monthly masked reviews by the Aerpio Clinical Safety Review Team (CSRT), and quarterly masked reviews by the Safety Assessment Committee (SAC: composed of members independent of the clinical team including Aerpio physician/cardiologist, a non- sponsor independent physician experienced in the assessment of clinical trial safety data, a 
non-sponsor independent physician with expertise in gastrointestinal/hepatology safety assessment, and a non-sponsor independent physician/ophthalmologist with expertise in ophthalmology safety assessment ).  Ad hoc review by any review committee will be conducted 
anytime an important safety signal is identified. If unmasked reviews are needed to understand a potential safety signal, these will be conducted by the SAC .  These reviews are detailed further in 
the AKB -9778 Safety Surveillance Plan .   
7 SELECTION AND WITHDRAWAL OF SUBJECTS 
7.1 General Criteria 
Subjects will be recruited for screening by investigative Sites.   
To be eligible for this study, a subject must provide valid informed consent and must meet all of the following criteria.  No study procedures (including screening tests) may be performed until after the informed consent process has been conducted and the subject has legally signed. 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 29 of 72 
 A subject number will be allocated to each subject at the Screening visit.  If during the course of 
the Screening tests and procedures, a subject does not meet the eligibility criteria or does not 
continue in the study, the subject will be considered a Screening failure (not a withdrawal). 
7.2 Subject Eligibility Criteria 
7.2.1 Subject-Level Inclusion Criteria 
1. Males and non-preg nant females between 18 to 80 years of age, inclusive. 
2. Body mass index (BMI) between 18 to 40 kg/m2, inclusive.  
3. Diagnosis of diabetes mellitus (type 1 or type 2).  Any one of the following will be considered to be sufficient evidence that diabetes is pres ent:  
a. Current regular use of insulin for the treatment of diabetes for at least the 3 months prior to screening. 
b. Current regular use of oral anti- hyperglycemia agents for the treatment of diabetes 
for at least the 3 months prior to screening. 
c. Documented diabetes (type 1 or type 2) as classified by the American Diabetes Association (ADA) and/or World Health Organization (WHO) criteria. 
4. At least one eye meets the study eye criteria listed below.  
5. Ability, in the opinion of the Investigator, and willingness to return for all scheduled visits and assessments.  
6. Ability to compliantly self -administer subcutaneous study medication twice daily for 12 
consecutive months.  
7. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure. 
7.2.2 Subject-Level Exclusion Criteria:  
1. For females of child -bearing potential: pregnant or breast-feeding or intending to become 
pregnant within the next 12 months.  
2. Females of child -bearing potential who are unable or unwilling to use an acceptable method 
of contraception (Refer to Section 9.1.3, Contraception and Pregnancy Avoidance Measures). 
3. Non-vasectomized male subjects who are unable or unwilling to use an acceptable method of 
contraception (Refer to Section 9.1.3, Contraception and Pregnancy Avoidance Measures). 
4. Hemoglobin A1C (HbA1C) ≥ 12.0% at Screening. 
5. Uncontrolled hypertension defined as resting (sitting) systolic BP of ≥180 mmHg or a 
diastolic BP of ≥100 mmHg at Screening.  Must be on a s table (≥ 6 weeks) antihypertensive 
regimen.  
6. Resting (sitting) systolic BP of < 100 mmHg at Screening.  
7. A history of symptomatic orthostatic hypotension, vasovagal syndrome, syncope, or presyncope within one year prior to Screening.  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 30 of 72 
 8. Initiation of nitrate medications or history of nitrate -associated orthostatic symptoms within 
one month prior to Screening. 
9. History of stroke, transient ischemic attack, congestive heart failure > NYHA Class 2, 
angina, or acute coronary syndrome within 3 months prior to Screening or any acute 
cardiology medical issues within 30 days prior to screening.  
10. Coronary-artery bypass graft, percutaneous intervention (e.g., cardiac, cerebrovascular, aortic), or major cardiac surgery within 3 months prior to Screening or anticipated need during study participation.   
11. If atrial fibrillation is present, then it must have been continuously present for >2 months 
with adequate rate control (ventricular response <95 BPM) with no plans to return the subject to sinus rhythm during the study confirmed by either their primary care physician or cardiologist.
  
12. QTcF > 470  ms.   
13. Major surgery within 28 days prior to Screening or major surgery planned during the study. Major surgery is defined as a surgical procedure that is more extensive than  fine needle 
biopsy/aspiration, placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter. 
14. Serum transaminase ([AST] and [ALT]) levels > 2X the upper limit of normal (ULN). (May be repeated once).  
15. History of clinically significant chronic liver disease  (defined as any complication of liver 
disease, ascites, varices, hepatic encephalopathy, hepatocellular cancer ). 
16. History of chronic renal failure (stage 4 or 5).  
17. History of gastrointestinal bleeding within the last year, or any history of bleeding due to arteriovenous ma lformation . 
18. Ferritin < 30 ng/ml in combination with a transferrin saturation ( TSAT ) < 20% . 
19. Fecal occult blood > 4.0 mg total hemoglobin/g feces  as determined by the central laboratory . 
20. Presence of New York Heart Classification congestive heart failure class III or IV.  
21. Severe aortic stenosis . 
22. Chronic anticoagulation with warfarin, a direct acting anticoagulant, or antiplatelet agent 
(other than low dose aspirin).  
23. History of any solid organ transplant or bone marrow transplant, requiring immunosuppressive medications.  
24. Any history of alcohol or drug abuse within the previous year prior to Screening. 
25. Previous treatment with AKB -9778. 
26. Use of an investigational medication or device or participation in an investigational study within 30 days or 5 half-lives of the investigational medication, whichever is longer, preceding Screening, or ongoing or scheduled participation in another investigational study during the current study.  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 31 of 72 
 27. Other severe acute or chronic medical or psychiatric condition or laboratory abnorm ality that 
may increase the risk associated with study participation or study drug administration or may 
interfere with the interpretation of study results and, in the Investigator’s judgment, would make the subject inappropriate for study entry. 
28. Current t reatment for serious systemic infection.  
29. History of allergy to fluorescein.  
30. Subject is expecting to move out of the area of the clinical site to an area not covered by another clinical site during the conduct of the study.  
7.3 Ocular Eligibility Criteria 
For a subject to be included in the study, at least one eye must meet all ocular inclusion and exclusion criteria. If both eyes meet all ocular eligibility criteria, then the eye with the worse ETDRS DRSS  should be designated the study eye, and the other e ye designated as a qualified 
fellow eye; in this case , the Central Image Reading Center will confirm selection of the study 
eye. 
7.3.1 Study Eye / Qualified Fellow Eye Inclusion Criteria: 
1. Moderate to severe NPDR (ETDRS Level 43 – 53 inclusive) as confirmed  by th e Central 
Image Reading Center  
2. No evidence of center involved DME on SD -OCT  as confirmed by the Central Image 
Reading Center   
3. No history of treatment for DME or DR within 12 months prior to Day 1 and no history of 
treatment with Iluvien® within 36 months prior to Day 1  
4. ETDRS BCVA letter score ≥ 70 (Snellen 20/40 or better) 
7.3.2 Study Eye /Qualified Fellow Eye Exclusion Criteria  
1. A decrease in visual acuity due to causes other than DR (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, previous vitreoretinal surgery, non- retinal 
condition, substantial cataract). 
2. Any other ocular disease that may cause substantial reduction in visual acuity, including iris neovascularization, retinal detachment, visually significant epiretinal membrane, 
vitreomacular traction, vitreous hemorrhage or fibrosis, ocular inflammation (uveitis), other 
retinal inflammatory or infectious diseases.  
3. Evidence of active ocular infection (e.g. , blepharitis, keratitis, scleritis, or conjunctivitis).  
4. History of non- infec tious uveitis . 
5. High myopia (-8 diopter or more correction). 
6. History of prior pars plana vitrectomy. 
7. History of prior PRP  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 32 of 72 
 8. Evidence of neovascularization on clinical examination, including active neovascularization 
of the iris or angle neovascularization  
9. Evidence of neovascularization on FA within the area of the Modified 7- Field  fundus 
photographs as confirmed by the Central Image Reading Center . 
10. History of any ocular surgery within 3 months prior to Day 1. 
11. Uncontrolled glaucoma defined as IOP ≥ 30 mmHg on maximum IOP reduction therapy.  
12. Media opacity , pupillary constriction (i.e. senile miosis), or poor subject cooperation that, in 
the opinion of the investigator, would interfere with any study procedures, evaluations or interpretation of data. 
13. Any ocular  condition that, in the opinion of the investigator, may require intervention, 
interfere with the study procedures, or interfere with evaluations of efficacy or safety or interpretation of data collected in the study. 
7.4 Waivers 
No waivers will be granted in the study. 
7.5 Replacement of Subjects  
Subjects withdrawn for reasons other than lack of efficacy  (treatment for PDR or DME) may  be 
replaced . 
7.6 Discontinuation of Study Medication/Withdrawal of Subjects  
Subjects will discontinue study medication for any of the  following conditions:  
• In the opinion of the Investigator, it is medically necessary  
• The subject withdraws consent 
• Major toxicity considered to be related to study medication 
• The investigator obtains the treatment code for the subject  
• Administrative reaso ns, such as, subject non-compliance or a major protocol violation 
• Upon request of the Subject, Sponsor, Institutional Review Board ( IRB) or regulatory 
agency  
• Study termination  
 
In addition to  the above reasons for study medication discontinuation, if the s ubject meets 
criteria for treatment of PDR or DME (e.g. Anti-VEGF, steroids, laser, vitrectomy) in the study 
eye or qualified fellow eye, study medication may  be discontinued at the discretion of the 
principal investigator and the subject. 
o Criteria for tre atment of PDR or DME in the study eye or qualified fellow eye are 
given in Appendix B . Non- qualified  fellow eyes may be treated at the discretion of 
the Investigator.  
o Refer to Section  8.4.3 for additional details regarding assessments to be conducted 
prior to treatment of PDR or DME.  
 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 33 of 72 
 Once it is identified that a subject will discontinue study medication, the subject should undergo 
all EOT ( Month 12/ Early Withdrawal) assessments (See Section  9.3.2.16) as soon as possible 
after study medication is stopped. The subject will then enter the 1 -month Follow-up period 
provided that the subject has not withdrawn consent. 
If a subject does not return for a scheduled site visit or complete a homecare nurse visit , every 
effort should be made to contact the subject.  In any circumstance, every effort should be made 
to document subject outcome by completing the End of Treatment ( Month 12/ Early 
Withdrawal) assessments.  
The Investigator must document the primary reason for discontinuation of study medication on the appropriate case report form (CRF).  If the reason for discontinuation of study medication is a clinical AE, monitoring will continue until the AE resolves or the Investigator assesses the AE as chronic or stabilized. 
8 STUDY PRODUCT AND TREATMENT OF SUBJECTS   
8.1  Study Medication, Supplies and Storage 
AKB -9778 and matching placebo will be provided as sterile pre- filled syringes .  The pre- filled 
syringes will be packaged in kits containing a one-week supply of study medication (seven “AM” doses and seven “PM” doses).  Kits will be shipped by the Sponsor or its designated 
supplier/distributor to the investigative site.  S tudy medication will be provided as masked 
supplies.  Syringes containing doses to be administered in the morning will be labelled “AM” and syringes containing doses to be administered in the evening will be labelled “PM”.    
The Investigator or designated study personnel will be responsible for study medication supply accountability ( Section 8.5) and dispensing study medication and supplies to subjects.  
AKB 9778 
AKB -9778 is supplied as a sterile solution for subcutaneous administration packaged in a clear 
glass pre -filled syringe sealed with a Flurotec -coated st opper.  Each syringe is filled to a volume 
of 0.75 mL which delivers a dose of 15 mg AKB-9778. 
The drug product formulation contains 20 mg/mL AKB -9778, 100 mg/mL HPβCD (United 
States Pharmacopeia [USP]) and 25 mg/mL dextrose, USP.  The formulation is controlled to pH 
5.0 - 8.5 with an osmolality of between 250 and 350 mOsm/kg. 
Placebo  
The matching placebo formulation is supplied as a sterile solution for subcutaneous 
administration packaged in a clear glass pre- filled syringe sealed with a Flurotec -coated s topper.  
Each syringe is filled to a volume of 0.75 mL.  
The placebo formulation ( PBS) contains 8 mg/mL sodium chloride, USP, 1.5 mg/mL sodium 
phosphate dibasic, USP, and 0.6 mg/mL sodium phosphate monobasic, USP.  The formulation is 
controlled to pH 5.0 - 8.5 with an osmolality of between 250 and 350 mOsm/kg. 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 34 of 72 
 8.1.1 Storage and Handling of Study Medication  
At the investigational site, study medication  will be locked under controlled access and 
maintained at USP/National Formulary (NF) Controlled Room Temperature 15ºC - 30ºC (59ºF - 
86ºF) inclusive, with excursions permitted of up to and including 40ºC (104ºF) for no more than 
24 hours.    
The subject will be directed to store study medication in a secure location away from children at 
ambient temperature . 
8.2 Dispensi ng Procedures  
Assignment of masked study medication for dispensing will be made using an interactive web  
response s ystem (IWRS) . 
The Investigator will maintain a Drug Accountability Form itemizing all masked medication dispensed to and returned from each subject during the study.   
At Day  1 and visits on Months 1 through 11, subjects will be provided with sufficient supply for 
1 month (4 weeks) of dosing plus overage to allow for some flexibility in study visit scheduling.  At the Day 1 visit, the subject w ill also be provided with a tote bag which contains ancillary 
supplies for dosing (e.g., sterile wipes, band aids, sharps container). Subjects should be instructed to bring all unused study medication to each monthly study visit 
for product accountability.  Full sharps containers should be returned and replaced as necessary.  Subject dosing diaries should be returned at each monthly visit and subjects will be questioned 
regarding dosing compliance and whether they have questions or have experienced any problems related to the dosing of study medication.   
All unused and returned study medication should be retained at the investigative site and must be 
returned to the Sponsor or its designee for destruction.  If authorized by the Sponsor, investigative sites that have SOPs for destruction of study medication on site may destroy  study 
medication once accountability procedures have been completed.  
8.3 Treatment of Subjects 
The Treatment  period will last 12 months ( 48 weeks).     
8.3.1 Treatment Group Assignments 
Subjects  meeting all eligibility criteria will be randomized 1:1 ;1 to either AKB -9778 15 mg  QD, 
AKB -9778 15 mg BID, or Placebo treatment groups.  Fifty (50) subjects are planned per group.  
The treatment groups are as follows:  
• Active Group: SC AKB -9778 15 mg (BID)  
• Active Group: SC AKB -9778 15 mg (QD) 
• Placebo Group: SC PBS (BID)  
8.3.2 Randomization and Allocation to Treatment Group 
Approximately 150 subjects will be treated in the study.   
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 35 of 72 
 Using a central IWRS randomization system, eligible subjects will be assigned in a double-
masked fashion 1:1:1  to one of the 3 treatment groups.  To maintain balance between treatment 
groups with respect to DR severity, randomization will be stratified by Screening ETDRS DRSS  
(levels 43, 47 and 53).  The number of study eyes randomized with Screening ETDRS DRSS 
level 43 will be capped at 50.  
8.3.3 Masking in the Study 
This study will be conducted in a double- masked manner.   
Treatment group assignment will be done through a central randomization system a nd completed 
using an IWRS.   
Study medication will be shipped as masked supplies.   All investigative site staff will be masked to study treatment assignment  
Subjects will be masked to treatment assignment during the entirety of the study.  
Central Image Reading Center personnel will be masked to treatment assignment for the entirety 
of the study and the reading and grading will be done in a masked fashion. Blood specimens will be obtained from subjects for PK analysis in a manner that maintains 
treatment masking. Select personnel at the bioanalytical contract laboratory will be unmasked to subject treatment in order to permit analyses of samples from active treatment  subjects only.  
8.3.4 Unmasking 
Unmasking of the Investigator is restricted to emergency situations and should only be used under circumstances where knowledge of the treatment is necessary for the proper management of the subject.  When possible, the Investigator should first discuss the unmasking request with the Sponsor and or Medical Monitor prior to unmasking.  If treatment is unmasked, the subjects should be discontinued from the study.  
8.3.5 Study Drug Administration 
Subjects will be responsible for self- administering study medication and will receive training 
during the Day 1 visit.   
On Day 1, Within 30 minutes to 1  hour prior to dosing, the subject should eat a meal or snack 
and drink 1- 2 glasses of fluids preferably juice or electrolyte-containing as per the subject's usual 
diet management.  
Following the first dose of study medication on Day 1, subjects should remain seated for the first 
30 minutes, when not conducting study assessments.  
On Day 1, subjects will be dosed with the AM dose at the site, regardless of the time of day.  Subjects will only self -administer the AM dose of study medicatio n on Day 1. The subject will 
self-inject BID on a morning and evening schedule as detailed below.  Subjects will dose BID 
except for  Day 1 when the subject will administer  the first dose of study medication at the site 
using the AM dose (regardless of the time of day ) and will begin the BID dosing schedule on 
Day 2; the PM dose will not  be administered on Day 1. Subjects will only use AM syringes for 
dose administration in the morning and PM syringes for dose administration in the evening. 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 36 of 72 
 Subjects should administer their daily doses around the same time every morning and evening, if 
possible. If a dose is missed, this dose should be skipped and the subject should maintain the 
morning and evening dosing schedule.  Subjects will maintain a study medication diary noting 
time and location of injection. Subjects should be encouraged to follow their normal diet and maintain fluid intake (per their diabetes management).  
Study medication will be administered subcutaneously in the abdomen (preferably) following standard subcutaneous administration practices.  A distance of at least 3  cm between injection 
site and the midline, and between injection site and any scar should be maintained.  The subject should avoid tender, bruised, red or indurated areas and should maint ain a distance of at least 
3 cm between consecutive injections.  If possible, subjects should not dose in the same quadrant of the abdomen between consecutive injections.  If the subject does not prefer to inject in the abdomen, the subject is allowed to dose in other standard regions for subcutaneous administration (e.g. , upper arm or thigh); the location of the injection site will be identified in the 
subject medication diary.  
For subjects on injectable hypoglycemic drugs (e.g. , insulin or GLP- 1 analogues ), it is preferable 
that a separate anatomical region be used for study drug administration.  For example, if the subject usually injects insulin or GLP-1 analogue in the upper arm, then study drug would preferably be injected in the abdomen. 
Before injection, the skin at the injection site should be cleaned and prepared with a skin 
disinfectant.  Care must be taken to ensure the study medication is not injected into a blood vessel.   
The subject must be able to compliantly self -administer study medication.  If the subject lives 
with a caretaker, the caretaker is allowed to assist the subject with dosing.  
8.4 Prior and Concomitant Therapy 
8.4.1 General  
All medications taken within 30  days prior to the start of study medication through the Month 12 
EOT vis it should be recorded on the appropriate CRF.   
Diabetes management is left to the subject’s medical care provider.   
Subjects will take allowed non -study medication including insulin or oral- hyperglycemia agents 
per their normal routine. (For additional details see Section 9.1.4).  
Procedural ophthalmic medications are not required to be recorded (e.g., fluorescein dye, dilating drops, etc.).  
8.4.2 Investigational Medications 
Study subjects should not have received any investigational medication or participated in an investigational study within 30  days or 5 half -lives of the investigational medication, whichever 
is longer, preceding Day 1. 
Additionally, ongoing or scheduled participation in another investigational study during the 
current study through the Month 12 visit is not allowed . 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 37 of 72 
 8.4.3 Treatment of PDR or DME  
Criteria for treatment of PDR or DME in the study eye or qualified fellow eye during the study 
are summarized in Appendix B . Treatment of PDR  of DME in a non-qualifi ed fellow eyes is at 
the discretion of the Investigator. Treatment will be recorded on the appropriate CRFs.  
Subjects who receive treatment for PDR or DME in a study eye  or qualified fellow eye may  
discontinue study medication at the discretion of the Investigator and subject. Subjects who remain in the trial will continue study medication .  
The following scenarios apply depending on eye being treated for PDR or DME. 
• For a study eye or qualified fellow eye requiring treatment, the Sponsor Medical Monitor 
should be informed prior to initiation of treatment. Additionally,  
o If the subject will discontinue study medication, the subject should undergo all 
EOT (Month 12/Early Withdrawal assessments ( See Section 9.3.2.16) as soon as 
possible after study medication is stopped. EOT procedures should be conducted 
prior to treatment for PDR or DME in the study eye  or qualified fellow eye . 
Treatment for PDR or DME will be in accordance with criteria in Appendix B ; 
following treatment, t he subject will enter the 1 -month Follow-up period.  
o If the subject will continue study medication, consult the Sponsor Medical 
Monitor to determine appropriate ocular assessments to be conducted prior to treatment for PDR or DME. Treatment for PDR or DME will be in accordance with criteria in Appendix B .  
• For a non- qualified fellow eye requiring treatment: 
o The subject wil l remain in the study and study assessments will be conducted per 
protocol prior to any treatment for PDR or DME. Treatment for PDR or DME in a non-qualified fellow eye is at the discretion of the Investigator.   
8.5 Product Accountability and Destruction  
Product accountability should be an ongoing process throughout the study.  All study medication 
must be accounted for and any discrepancies explained.   
Proper drug accountability includes, but is not limited to: 
• Continuously monitoring expiration dates if expiry date or retest date is provided to the 
Investigator. 
• Frequently verifying that actual inventory matches documented inventory. 
• Verifying that the master drug log is completed for all subcutaneous study medication received at the site and that all required fields are complete, accurate, and legible.  
• Review of temperature log, and that the study medication is stored in locked access controlled conditions. 
• Verifying the subject individual drug accountability log is completed for each subject and that al l required fields (units dispensed, returned, used, compliance) etc., are complete 
accurate and legible.  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 38 of 72 
 If any dispensing errors or discrepancies are discovered, the Sponsor must be notified 
immediately.  
Prior to site close -out, a representative from the Sponsor will perform clinical study material 
accountability and reconciliation.  
At the end of the study, the Investigator will retain all the original documentation regarding clinical study material accountability, return, and/or destruction, and copies wi ll be sent to the 
Sponsor. 
The Investigator or designated study personnel is responsible for keeping accurate records of the 
study medication received from the Sponsor or its designee, all supplies retained in inventory at 
the site, and study medication dispensed to and returned from each subject.  This record will be maintained on a Drug Accountability Log that accurately reflects the accountability of the study medication at all times.  
During the study, the Investigator will be notified of any expiry date s or retest date extensions of 
study medication.  If an expiry date notification is received during the study, the site must complete all instructions outlined in the notification, including segregation of expired study material for return to the Sponsor or its designee for destruction. 
At the end of the study, any unused study medication must be returned to the Sponsor or its 
designee for destruction.  If an investigative site has SOPs for destruction of study medication on 
site, the Sponsor may authorize destruction of at the investigative site following completion of accountability procedures.  
9 STUDY PROCEDURES AND SCHEDULE OF ACTIVITI ES  
Please see Appendix A  for a detailed table of the Schedule of Activities.  
A one-month duration in this study is defined as 4 weeks/28 days. The 12- month Treatment 
period is 48- weeks/ 336 days.  
This study includes the following periods and visits: 
• Screening visit (up to 28 days prior to Baseline) 
• Baseline visit (pre -dosing period on Day 1) 
• Treatment Period (Days  1 through Month 12 ( Week 48)); including : 
o Investigative site visits on Day  1, Day 7 (phone -call),  and monthly ( i.e., every 4 
weeks) thereafter until the Month 12 (Week 48) EOT  visit  
o Homecare nurse visits on Screening and Months 3, 6, 9, 12 ( EOT)   
• Follow-Up Period 1 Month (4 weeks ) Post -Treatment  
The following sections describe the procedures to be completed during the study.  Subjects are to be assessed by the same Investigator or site personnel whenever possible.    
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 39 of 72 
 9.1 Administrative Procedures  
9.1.1 Informed Consent Procedure 
Informed consent must be obtained prior to the subject entering into screening for the study and 
before any protocol- specific procedures are performed (see Section 15.3).  
9.1.2 Documentation of Screen Failures 
Investigators will maintain a log of pre -screened subjects and indicate who was brought in for 
informed consent and Screening or who was not.  For subjects not brought in for informed consent and Screening, the reason(s) for not passing the pre-screen will be documented by the Investigator. 
Investigators must account for all subjects who sign informed consent and will maintain a log of 
subjects screened and indicate who was randomized or screen-failed.  If the subject is found not to be eligible prior to randomization, the reason(s) for ineligibility/screen fail must be documented by the Investigator. 
Subject numbers assigned to subjects who fail screening will not be re-used. 
9.1.3 Contraception and Pregnancy Avoidance Measures 
 Summary of AKB- 9778 Reproductive Toxicology Studies  
In nonclinical animal embryo -fetal development studies, there was no evidence of external fetal 
teratogenic effects, or of skeletal or visceral malformations, at dose levels up to the highest doses 
tested; 180 mg/kg/day in rats and 140 mg/kg/day in rabbits. In rats and rabbits, decreased 
maternal body weight and food consumption were observed at these high doses.   
Fertility and peri-postnatal development studies have not yet been conducted with AKB-9778, 
and there are no data on the transmission of AKB-9778 in breast milk or the effect of AKB-9778 
on infants. 
 Guidance for Study AKB-9778- CI-5001 
Due to the unknown effects of AKB-9778 on sperm and the developing fetus, all subjects must agree to use adequate contraception throughout the study and for 30 days after administration of last dose of any study medication .  
Adequate contraception is defined as follows: 
Female subjects must be surgically sterile, postmenopausal (for at least one year), or have 
negative pregnancy test results at Screening (serum) and at Baseline (urine).  
Female subjects not surgically sterile or postmenopausal (for at least one year), and non-
vasectomized male subjects must practice at least one of the following methods of birth control: 
• total abstinence from sexual intercourse (minimum one complete menstrual cycle prior to Screening visit, throughout the study, and for 30 days after the last dose of study medication)  
• a vasectomized partner or partner of non-child bearing potential 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 40 of 72 
 • hormonal contraceptives (oral, parenteral, Nexplanon, or transdermal) for at least three 
months prior to study drug administration  
• double-method of birth control and must include condoms in addition to one other method: spermicide, IUD, diaphragm with spermicide, hormonal contraceptive, bilateral tubal ligation, Essure procedure.  
Female subjects  may not donate eggs (ova, oocytes) during this study and for 30 days after the 
last dose of study medication . 
Male subjects must not donate sperm during the study and for at least 60 days after the last dose 
of any study drug . 
9.1.4 Diet, Fluid and Activity Control  
Subjects should be encouraged to follow their normal diet and maintain fluid intake (per thei r 
diabetes management).  
Subjects will take allowed non -study medication including insulin or oral- hyperglycemia agents 
per their normal routine.  Subjects will monitor blood sugar as per their normal routine.  Diabetes management is left to the subject’s medical care provider.  
Subjects are to refrain from physical activity greater than their normal level of activity for the duration of the study.  
Subjects will be advised that it is important to refrain from excessive alcohol intake for the 
duration of the study.   
Subjects taking medication for erectile dysfunction ( e.g., Viagra ®, Cialis ®, Levitra ®), should 
not take this medication within 2 hours before or after study medication.  For three days prior to and during  the days of stool sample collection for fecal occult blood testing, 
subjects are to refrain from eating  any red meat (beef, pork or lamb). Also, for three days before 
and during the days of stool sample collection, subjects will avoid taking aspirin.  However, 
subjects taking daily low dose aspirin are allowed to continue their aspirin but must not change 
their dose.  
On Day 1  and on Month 6, within 30 minutes to 1  hour prior to dosing at the site , the subject 
should eat a meal or snack and drink 1- 2 glasses of fluids preferably juice or electrol yte 
containing as per the subject's usual diet management.  Following dosing on the Day 1 and 
Month 6 visits, subjects should remain seated for the first 30 minutes, when not conducting study 
assessments.   
9.1.5 Laboratory Accreditation and Reference Ranges 
The Investigator and the Sponsor will maintain a copy of the laboratory accreditation and the 
reference ranges for the central laboratory used for clinical laboratory evaluations.   
9.2 Study Procedures and Evaluations  
Please see the Schedule of Activities presented in Appendix A for designated time points for 
assessments.  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 41 of 72 
 9.2.1 Clinical Evaluations  
The following clinical evaluations will be conducted during the course of the study.   
• Medical /ophthalmic  history and demographics :  Relevant medical history (with particular 
emphasis on previous medical conditions that may lead to exclusion) and significant 
ongoing medical conditions or diseases should be documented. Ophthalmic history should include treatment history for DR/DME. 
• Body System Assessments:  Body systems to be evaluated include general appearance, 
HEENT (head, ears, eyes, nose and throat), cardiovascular, respiratory, abdomen/gastrointestinal (including query of any changes in bowel habit frequency, consistency, or color), musculoskeletal, and skin (including query of any skin abnormalities noted as well as direct observation of skin of head, neck, chest, abdomen, back and extremities) . Subjects will be instructed that if they note any abnormalities 
between visits they should contact their study doctor so that any such findings can be assessed .  
• Height  (at Screening  only), weight , and temperature  
• 12-Lead ECG :  A standard 12- lead ECG will be obtained after the subject has been 
resting comfortably in a supine position for approximately 5 minutes and prior to vital sign assessments and blood draws when possible.  With the subject in a supine position, obtain the 12- lead tracing.  Each 12-lead ECG must be recorded with a paper speed of 
25 mm/sec and printed as a paper copy.   The Investigator (or a qualified observer) will 
interpret the ECG and record the results including the following parameters: heart rate, PR interval, QT interval, QRS interval, and QTcF (corrected). 
In some cases, it may be appropriate to repeat abnormal E CGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads are placed in the same positions each time in order to achieve precise ECG recordings.  If a machine -
read QTcF value is prolonged, repeat measuremen ts may not be necessary if a qualified 
physician’s interpretation determines that the QTcF values are in the acceptable range.  
All abnormal rhythms will be reviewed by the study physician for the presence of rhythms of potential clinical concern.  The Inve stigator should utilize medical judgment 
in the reporting of AEs and SAEs as well as determination of additional cardiac work-up.  A printed record of the tracing(s) of the clinically significant rhythm(s) will be made and retained with other source documents. An ECG will be performed at the Screening, Month 6, and Month 12 (EOT) visits. 
• Vital Signs: Vital signs include blood pressure and heart rate.  Vital sign assessments 
should be taken prior to blood draws when possible. The subject should be seated, with legs uncrossed and feet resting comfortably on the floor, for at least 5 minutes prior to measuring blood pressure and heart rate. 
• ETDRS Best Corrected Visual Acuity (BCVA):   Visual acuity of both eyes will be 
assessed using the ETDRS protocol at 4 me ters.   
• Slit Lamp Biomicroscopy:  Slit-lamp biomicroscopy will include examination of the 
cornea, conjunctiva, anterior chamber, iris/pupil, lens, and eyelid of both eyes.  Findings 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 42 of 72 
 will be graded as normal, abnormal  not clinical ly significant, or abnormal clinically 
significant.     
• Intraocular Pressure (IOP):  IOP will be assessed with either applanation tonometry or 
tonopen; the method should be consistent throughout the study. 
• Dilated Indirect Ophthalmoscopy: Dilated indirect ophthalmoscopy will be performed to 
assess the vitreous, macula, optic nerve, and peripheral retina of both eyes.  Findings will 
be graded as normal, abnormal not clinical ly significant, or abnormal clinically 
significant.     
• SD OCT : Spectral domain optical coherence tomography ( SD OCT ) will be utilized to 
assess retinal  characteristics of both eyes. The OCT instrument type used throughout the 
study must be consistent for an individual subject. OCT imaging data will be transmitted to a central reading center for independent analysis. De tailed instructions for imaging and 
data transfers will be provided in the study- specific imaging manual. 
• Fundus Photography : Modified 7-Field or 4- Wide Field color fundus photographs 
(including red free images) of both eyes will be taken to evaluate retinal anatomy.  Photographs will be transferred to a central reading center.  Detailed instructions for imaging and data transfers will be provided in the study- specific imaging manual.  
o For sites participating in the UWF imaging sub -study, in  addition  to Modified 7-
Field or 4- Wide Field color fundus photographs, UWF color fundus photographs 
should be taken using the Optos P200Tx or Optos California system. Parameters 
obtained are detailed further in this section under “UWF imaging”.  
• Fluorescein Angiograph y (FA) : Retinal vasculature of both eyes will be evaluated by 
fluorescein angiography (FA).  FA images will be transferred to a central reading center.  Detailed instructions for imaging and data transfers will be provided in the study -specific 
imaging  manual . 
o For sites participating in the UWF imaging sub -study, in  lieu of standard FA, 
UWF FA images should be taken using the Optos P200Tx or Optos California 
system. Parameters obtained are detailed further in this section under “UWF 
Imaging”.  
• Adverse Event Assessments:  Beginning with informed consent and through final 
protocol required  visit, the Investigator and study personnel will review each subject’s 
laboratory and clinical evaluation findings and query the subject directly regarding AEs (see Section 
10).  If a home healthcare nurse identifies any potential AEs during a home 
visit, the nurse will communicate directly to the study site and the Investigator will be responsible for determination of AEs and any necessary follow-up with the subject. Subjects must be followed for AEs until the final required protocol visit or until all drug-related toxicities and serious adverse events have resolved (or  are considered 
chronic/stable), whichever is later.   
• Concomitant Medication Recording:  All medications, both prescription and non-
prescription, and including vitamins, herbals, topicals, inhaled, and intranasal, taken within 30 days prior to the start of study medication and through the Month 12 EOT visit 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 43 of 72 
 should be recorded on the appropriate CRF.  At each study visit, subjects will be asked 
whether they have started or discontinued any medication since their previous study visit.  This includes single use or PRN (as needed) medication use.  All medications and treatments, including vitamin supplements, over-the-counter medications, and oral herbal preparations must be recorded in the CRFs.   
• Exploratory Efficacy Sub-Study Evaluations (to be conducted at a subset of sites):  
o OCT -A – OCT -angiography should be obtained from both eyes using a SD OCT  
machine according to instructions provided by the manufacturer  
o ERG – Flicker ERGs will be obtained from both eyes using the RETeval system 
(LKC Technologies, Gait hersburg MD). Responses will be obtained from 
electrodes placed on the skin under light- adapted conditions. Parameters obtained 
will include flicker ERG amplitude, ERG peak latency, and pupillary response to 
each of 3 different flicker intensities . RETeval  score will also be derived from 
these data (Maa et al, 2015).   
o UWF imaging  – UWF FA and UWF color fundus photographs will be obtained 
using the Optos P200Tx or Optos California instrument following procedures specified in the study specific imaging manual.  As described previously, UWF 
FA will be performed in  lieu of standard FA, but UWF photographs will be 
obtained in  addition  to standard Modified 7-Field or 4- Wide Field  color fundus 
photographs. UWF fundus photographs are only obtained on visits when UWF 
FA is performed (e.g. Screening, Month 6, and Month 12 (EOT). Parameters 
obtained from UWF FA include area of peripheral non-perfusion, area of peripheral leakage. Parameters measured in UWF color fundus photographs 
include peripheral microaneurysms, vitreous hemorrhage, venous beading, intra -
retinal microvascular abnormalities ( IRMA ) and neovascularization elsewhere 
(NVE) .  
9.2.2 Laboratory Evaluations :  
All samples collected (with the exception of urine pregnancy tests) will be sent to a central 
clinical labor atory.   
If to be conducted at the same time points, blood sampling should occur after vital sign assessments and ECGs have been conducted.  
Samples for clinical laboratory evaluations (hematology, chemistry, fecal occult blood testing, 
and urinalysis assays) and Screening serum pregnancy tests will be analyzed at the central 
laboratory.  The Investigator is responsible for reviewing laboratory results for clinical significance.  
The central laboratory is also responsible for distribution of PK samples t o the respective PK 
laboratory for analysis.  Once the results of the study are known, the Sponsor will determine if biomarker and genetic analyses will be conducted and will direct the central clinical laboratory 
on distribution of samples for biomarker and genetic analyses to the appropriate laboratories .    
The following clinical laboratory evaluations will be conducted during the course of the study: 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 44 of 72 
 • Pregnancy test :  A serum pregnancy test will be performed at Screening for females of 
childbearing potential.  The investigative site will perform a urine pregnancy test at the 
Baseline, Month 6 and Month 12 EOT visits .  The Screening and Baseline results must be 
available and must be negative before the subject takes the first dose of any study medication o n Day 1.  At each monthly visit, the site will query subjects of childbearing 
potential regarding the potential for pregnancy.  
• Hematology :  The complete blood count (CBC) will include: hemoglobin (Hgb), 
hematocrit, red blood cell (RBC) count, mean corpuscular (cell) volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), 
red cell distribution width (RDW), mean platelet volume (MPV), white blood cell (WBC) 
count with differential (neutrophils, immature granulocytes, lymphocytes, monocytes, eosinophils, basophils), platelet  count, reticulocyte count and HbA1C. Hematology will 
be assessed every other month except for HbA1C which will be assessed at Screening, Baseline, Month 6, and Month 12 (EOT) visits.    
Chemistry :  The serum chemistry will include the following assays: sodium, potassium, 
bicarbonate, chloride, calcium, phosphorus, glucose, creatinine, blood urea nitrogen (BUN), creatinine phosphokinase (CPK), uric acid, albumin, total protein, total bilirubin, alkaline phosphatase, alanine transaminase ((ALT (SGPT)), aspartate transaminase (AST (SGOT)), lactate dehydrogenase (LDH), total cholesterol, triglycerides,  ferritin,  serum 
iron, total iron binding capacity ( TIBC ) and  transferrin saturation ( TSAT ). Chemistrie s 
will be assessed monthly. eGFR will be determined on serum chemistry samples 
collected at the Screening, Baseline, Month 6, Month 9, and Month 12 (EOT) visits.  
• Fecal occult blood testing: A small amount of stool will be collected on 3 separate days 
as per standard procedure to measure fecal blood levels using the HemoQuant test 
(Rockey et al, 1999; Barber et al, 2002; Harewood et al, 2002 ).  At the Screening, Month 
6, Month 9, and Month 12 (EOT) site visits, Investigative  sites  will distribute instructions 
and supplies for home specimen collection to the subject. For 3 days prior to and during 
the days of stool sample collection, subjects will refrain from eating red meat and taking 
high dose aspirin as detailed in Section 9.1.4. Subjects will collect their specimens and are responsible for shipping to the central laboratory for testing ; specimen collection and 
shipping should be conducted within one week following the site visit.  
• Urinalysis: Urinalysis will include bilirubin, blood , glucose, ketones, pH, protein, specific 
gravity and microscopic examination (only if urinalysis is positive for blood or protein).   
• Urine-albumin -to-creatinine ratio ( UACR ): UACR  will be determined on urine samples 
collected at the Baseline, Month 6, Month 9, and Month 12 ( EOT ) visits; subjects should 
refrain from heavy exercise 24 hours before these visits . 
• Pharmacokinetic analysis :  Analysis of plasma samples for AKB -9778 concentration 
determinations will be performed by a central PK laboratory using a validated Liquid Chromatography- Mass Spectrometry and Liquid Chromatography -Tandem Mass 
Spectrometry (LC -MS/MS) method.  Detailed instructions for processing and shipment 
of samples will be provided by the Sponsor or Central laboratory   
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 45 of 72 
 • Biomarker analysis in Plasma:  Biomarkers will be assessed in plasma samples.  Detailed 
instructions for processing and shipment of samples for biomarker analyses will be 
provided by the Sponsor or Central laboratory. 
• Genetic analysis:   Detailed instructions for processing and shipment of samples for 
biomarker analyses will be provided by the Sponsor or Central laboratory. 
9.3 Schedule of Activities  
The Schedule of Activities is presented in Appendix A and shows the timing of planned study 
procedures to be conducted at the study site and at the home care nursing visits.  Every effort should be made to adhere to the procedure schedule and a ll assessm ents should be completed at 
each study visit.  
The Screening, Baseline, Treatment , and Follow- up Periods will require subject participation for 
approximately 56 weeks. 
Study procedures, clinical assessments (including laboratory assays), and PK, biomarker and genetic sampling will be performed as indicated in the Schedule of Activities.   
Subjects will be responsible for self-administration of study medication which is provided in prefilled sterile syringes.  The subject will self -inject BID on a morning and evening schedule as 
detailed in Section 8.3.5.  Subjects will dose BID with the exception of Day 1 when the subject 
will dose the first ( AM) dose at the clinic  and will begin the BID dosing schedule on Day 2. No 
PM dose will be taken on Day 1.  
At the visit on Day 1, the site will train the subject on SC study medication administration and 
dosing diary completion.  After the pre- dose activities have been completed, the subject will self -
administer the AM dose of study medication.  
After t he subject has completed the EOT visit, no further subcutaneous dosing will occur. 
Study visits on Day 1, Month 6 and Month 12 EOT  should be scheduled for the morning.  The 
remainder of the site visits should also be scheduled for the morning when possible. Subjects will 
maintain a daily study medication diary and will record timing and location of dose. 
At the site visits on Day  1 and Months 1 through 11, subjects will be dispensed subcutaneous 
study medication and dosing supplies. Subjects discontinuing study medication sooner than the planned 12-month dosing period or 
withdrawing from the study should complete the Month 12 EOT assessments including the EOT assessments at the EOT site visit (See Section 9.3.2.16) and the EOT homecare nurse visit (See 
Section 9.3.3.5).  
Detailed descriptions of procedures and activities to be followed during each site and homecare nurse visit are presented in the following sections.  For specific time points please refer to the Schedule of Activities in Appendix A .  Procedures and activities to be conducted at the 
investigative site are presented in Section 9.3.2 followed by procedures to be conducted at the 
homecare nu rse visits presented in Section  9.3.3.   
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 46 of 72 
 9.3.1 Visit Windows  
Plasma PK samples collected at 30  and 90 minutes after dosing of study medication on Day 1 
and Month 6 should be collected within ±10 minutes of the target time.  If for any reason, the 
sampling time point for a given sample falls outside of the visit window, the sample must still be 
collected.  For all samples; the exact time of sample collection will be recorded.  
Blood pressure and heart rate evaluations performed must be conducted within ±20 minutes of the designated time.   
Subjects will only use AM syringes for dose administration in the morning and PM syringes for dose administration in the evening. Subjects should administer their daily doses around the same time every morning and evening, if possible. If a dose is missed, this dose should be skipped and 
the subject should maintain the morning and evening dosing schedule. 
The Day 7 phone call must be conducted within ±3 days.  
Site visits scheduled for Months 1 through 12 should be conducted within 28 days times the 
study month number ±3 days relative to the baseline visit (e.g. Month 1 visit window is 28 ±3 days from Day 1, Month 2 visit window is 56 ±3 days from Day 1, etc.).   
Homecare nurse visits scheduled  for Screening, Months 3, 6, 9 and 12 should be conducted 
within 1 week after the corresponding site visit. The Follow-up homecare visit occurs 4 weeks 
±3 days  after the EOT visit at the site.   
The fecal occult blood specimen collection and shipping to the Central Laboratory should be 
conducted by the subject within the week following the corresponding site visit.  
9.3.2 Activities to be conducted at the Study Site 
 Screening Visit   
The Screening visit must be performed within 28 days prior to dosing.  The Investigator will maintain a log of subjects screened and indicate who was enrolled or excluded and the reason for exclusion ( Section 9.1.2).  
After obtaining informed consent and receiving a unique subject number, subjects will undergo a number of screening activities.   
If possible, all screening activities should be conducted on the same day.  At the Screening visit, 
the following activities/procedures will be  performed: 
• Informed consent obtained 
• Assignment of subject number 
• Review of eligibility criteria  
• Demographics 
• Medical /ophthalmic history including treatment history for DR/DME  
• Temperature, h eight and weight 
• 12 Lead ECG ( prior to vital signs and blood draws) 
• Vital signs: 
o sitting  blood pressure and heart rate measurements  
• Eye and Vision Exams: 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 47 of 72 
 o ETDRS BCVA  
o slit-lamp biomicroscopy 
o IOP 
o dilated indirect ophthalmoscopy 
o SD OCT  
o fundus photography (and UWF fundus photography at select sub- study sites)   
o fluorescein angiography  (or UWF fluorescein angiography at select sub -study 
sites)  
• Laboratory Procedures  
o serum pregnancy test for women of childbearing potential 
o hematology 
o clinical chemistry  
• Concomitant Medication recording 
• AE monitoring 
• Dispense instructions and kit for subject to perform home fecal occult blood specimen 
collection   
 Baseline Period (Pre- Treatment, Day  1)  
Eligible randomized subjects  will be dosed at the Site on Day 1.  At Baseline on Day 1, the 
following activities/procedures will be performed prior to any dosing of study medication: 
• Interim medical/ophthalmic history 
• Vital signs (to be performed within 2 hours prior to dosing and prior to blood draws): 
o sitting  blood pressure and heart rate measurements  
• Eye and Vision Exams: 
o ETDRS BCVA  
o slit-lamp biomicroscopy 
o IOP 
o dilated indirect ophthalmoscopy 
o ERG (at select sub-study sites)  
o OCT -A (at select sub-study  sites)  
• Laboratory Procedures  
o urine pregnancy test  for women of childbearing potential (results must be known 
prior to dosing) 
o hematology 
o clinical chemistry  
o urinalysis 
o biomarker blood sampling 
o blood sampling for genetic analysis 
• Concomitant Medication recording as needed  
• AE monitoring 
 Treatment  Period – Day  1 
Following Baseline on Day 1, the following activities/procedures will be performed at the site  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 48 of 72 
 • Train subject on self-administration of study medication and diary completion.  Distribute 
diaries.  
• Subjects should eat a snack or meal and drink 1- 2 glasses of fluid (See Section 9.1.4) 
within 1  hour to 30 minutes prior to dosing.  
• Dose administration:  
o Subjects will self -dose the AM dose in the seated position and remain seated for 30 
minutes following dosing.  
• Sitting  blood pressure and heart rate measurements will be conducted at 30 and 90 
minutes  after dosing.  These assessments are to be conducted prior to any blood draws. 
o If a subject develops symptoms of lightheadedness, presyncope, or of possible 
hypotension, consistent with medical practice it is recommended that the blood pressure and heart rate be re-measured and the subject placed in the supine position until symptoms resolve. The Investigator should also contact the study medical monitor.
  
• PK blood sampling at 30 and 90 minutes after dosing.  Sampling is to be conducted after 
blood pressure and heart rate measurements are completed.  
• AE monitoring 
• Concomitant Medication recording as needed  
• Dispense 1  month supply of study medication kits and study medication diary. 
 Treatment  Period – Day  7 (Week  1 Phone call) 
• AE monitoring and AE recording since last visit  
• Question subject regarding dosing compliance and whether they have questions or have 
experienced any problems related to the dosing of study medication  
 Treatment  Period – Month 1 Visit (Week 4) 
• Vital signs: 
o sitting blood pressure and heart rate measurements  
• Eye and Vision Exams: 
o ETDRS BCVA  
• Laboratory Procedures  
o clinical chemistry  
• AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit  
• Collect return ed used supplies and review medication use since last visit  
• Dispense 1 month supply of study medication kits  
 Treatment Period – Month 2 Visit (Week 8) 
• Vital signs: 
o sitting blood pressure and heart rate measurements  
• Eye and Vision Exams: 
o ETDRS BCVA  
• Laboratory Procedures  
o hematology 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 49 of 72 
 o clinical chemistry  
• AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit  
• Collect return ed used supplies and review medication use since last visit  
• Dispense 1 month supply of study medication. 
 Treatment Period – Month 3 Visit (Week 12) 
• Vital signs  
o sitting  blood pressure and heart ra te measurements  
• Eye and Vision Exams: 
o ETDRS BCVA  
o slit-lamp biomicroscopy 
o IOP 
o dilated indirect ophthalmoscopy 
o SD OCT  
o fundus photography 
o ERG (at select sub-study sites)  
o OCT -A (at select sub-study  sites)  
• Laboratory Procedures  
o clinical chemistry  
• AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit  
• Collect return ed used supplies and review medic ation use since last visit  
• Dispense 1 month supply of study medication kits 
 Treatment Period – Month 4 Visit (Week 16) 
• Vital signs  
o sitting  blood pressure and heart rate measurements  
• Eye and Vision Exams: 
o ETDRS BCVA  
• Laboratory Procedures  
o hematology  
o clinical chemistry  
• AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit  
• Collect return ed used supplies and review medication use since last visit  
• Dispense 1 month supply of study medication kits  
 Treatment Period – Month 5 Visit (Week 20) 
• Vital signs  
o sitting  blood pressure and heart rate measuremen ts 
• Eye and Vision Exams: 
o ETDRS BCVA  
• Laboratory Procedures  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 50 of 72 
 o clinical chemistry  
• AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit  
• Collect return ed used supplies and review medication use since last visit  
• Dispense 1 month supply of study medication kits  
 Treatment Period – Month 6 Visit (Week 24) 
Given that post- dose PK sample collection is included in this visit, subjects will be 
instructed to not administer their AM dose prior to their visit and to bring their AM dose 
along with other study medication in kits, as the AM dose will be administered in the 
clinic.   
 
• Weight  and Temperature 
• 12 Lead ECG (prior to vital signs and blood draws) 
• Vital signs  
o sitting  blood pressure and heart rate measurements  
• Eye and Vision Exams: 
o ETDRS BCVA  
o slit-lamp biomicroscopy 
o intraocular pressure 
o dilated indirect ophthalmoscopy 
o SD OCT  
o fundus photography (and UWF fundus photography at select sub- study sites)  
o fluorescein angiography (or UWF fluorescein angiography at select sub -study 
sites)  
o ERG (at select sub-study sites)  
o OCT -A (at select sub-study  sites)  
• Laboratory Procedures  
o urine pregnancy test for women of childbearing potential  
o hematology  
o clinical  chemis try 
o urinalysis 
• Subjects should eat a snack or meal and drink 1- 2 glasses of fluid (See Section 9.1.4) 
within 1  hour to 30 minutes prior to dosing.  
• Dose administration:  
o Subjects will self -dose AM dose in the seated position and remain seated for 30 
minutes following dosing.  
• Sitting blood pressure and heart rate measurements will be conducted at 30 and 90 
minutes after dosing.  These assessments are to be conducted prior to any blood draws. 
• PK blood sampling at 30 and 90 minutes after dosing.  Sampling is to be conducted after blood pressure and heart rate measurements are completed.  
• AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit  
• Collect return ed used supplies and review medication use since last visit  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 51 of 72 
 • Dispense 1 -month supply of study medication kits 
• Dispense instructions and kit for subject to perform home fecal occult blood specimen 
collection    
 Treatment Period – Month 7 Visit (Week 28) 
• Vital signs  
o sitting  blood pressure and heart rate  
• Eye and Vision Exams: 
o ETDRS BCVA  
• Laboratory Procedures  
o clinical chemistry  
• AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit  
• Collect return ed used supplies and review medication use since last visit  
• Dispense 1 month supply of study medication kits 
 Treatment  Period – Month 8 Visit (Week 32) 
• Vital signs  
o sitting  blood pressure and heart rate  
• Eye and Vision Exams: 
o ETDRS BCVA  
• Laboratory Procedures  
o hematology 
o clinical chemistry  
• AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit  
• Collect return ed used supplies and review medication use since last visit  
• Dispense 1 month supply of study medication kits 
 Treatment Period – Month 9 Visit (Week 36) 
• Vital signs  
o sitting  blood pressure and heart rate measurements  
• Eye and Vision Exams: 
o ETDRS BCVA  
o slit-lamp biomicroscopy 
o intraocular pressure 
o dilated indirect ophthalmoscopy 
o SD OCT  
o fundus photography 
o ERG (at select sub-study sites)  
o OCT -A (at select sub-study  sites)  
• Laboratory Procedures  
o clinical chemistry  
o urinalysis 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 52 of 72 
 • AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit  
• Collect return ed used supplies and review medication use since last visit  
• Dispense 1 month supply of study medication kits 
• Dispense instructions and kit for subject to perform home fecal occult blood specimen 
collection   
 Treatment Period – Month 10 Visit (Week 40) 
• Vital signs  
o sitting  blood pressure and heart rate  
• Eye and Vision Exams: 
o ETDRS BCVA  
• Laboratory Procedures  
o hematology 
o clinical chemistr y 
• AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit  
• Collect return ed used supplies and review medication use since last visit  
• Dispense 1 -month supply of study medication kits 
 Treatment Period – Mo nth 11 Visit (Week 44) 
• Vital signs  
o sitting  blood pressure and heart rate 
• Eye and Vision Exams: 
o ETDRS BCVA  
• Laboratory Procedures  
o clinical chemistry  
• AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit 
• Collect return ed used supplies and review medication use since last visit  
• Dispense 1 -month supply of study medication kits  
 Treatment Period – Month 12 End of Treatment Visit (Week 48) 
• 12 Lead ECG (prior to vital signs and blood draws) 
• Weight and te mperature  
• Vital signs  
o sitting  blood pressure and heart rate measurements  
• Eye and Vision Exams: 
o ETDRS BCVA  
o slit-lamp biomicroscopy 
o intraocular pressure 
o dilated indirect ophthalmoscopy 
o SD OCT  
o fundus photography (and UWF fundus photography at select sub- study sites)  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 53 of 72 
 o fluorescein angiography (or UWF fluorescein angiography at select sub -study 
sites)  
o ERG (at select sub-study sites)  
o OCT -A (at select sub-study  sites)  
• Laboratory Procedures  
o urine pregnancy test  
o hemat ology 
o clinical chemistry  
o urinalysis 
o biomarker blood sampling 
• AE monitoring and AE recording since last visit  
• Concomitant Medication recording as needed since last visit  
• Collect return ed used supplies and review medication use since last visit 
• Dispense instructions and kit for subject to perform home fecal occult blood specimen 
collection   
9.3.3 Activities to be conducted at the Homecare nurse visit 
Homecare nurse visits scheduled for Screening, Months 3, 6, 9 and 12 should be conducted 
within 1 week after the corresponding site visit. The Follow-up homecare visit occurs 4 weeks ±3 days after the EOT visit at the site. Nurse visits will likely occur at subject’s  home; however 
alternate locations acceptable to the subject  are allowed (e.g. investigative site).   
Investigative sites will distribute instructions and kits for the subject to perform home fecal 
occult blood specimen collection and shipping to the Central Laboratory ; nurses will review 
status of specimen collection and shipping with subjects on corresponding homecare visits .     
During homecare nurse visits, if any change in status, the nurse will contact the Investigator, so that the Investigator can assess for any new adverse event or change in status of existing adverse event, and document and report accordingly.  
 Screening Visit  
• Body systems assessment  
• Review Status of f ecal occult blood testin g 
 Treatment Period – Month 3 Visit (Week 12) 
• Body systems assessment  
 Treatment Period – Month 6 Visit (Week 24) 
• Body systems assessment  
• Review status of fecal  occult blood testing 
 Treatment Period – Month 9 Visit (Week 36) 
• Body systems assessment   
• Review status of fecal  occult blood testing 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 54 of 72 
 
 Treatment Period – Month 12 Visit (Week 48) 
• Body systems assessment  
• Review status of fecal  occult blood testing  
 Follow-up Period -1 Month (4 week s) Post- Treatment Visit (Week 52)  
• Medical history since last visit  
• Body systems assessment  
 
10 ADVERSE EVENTS  
10.1 Definitions 
10.1.1  Adverse Events (AEs) 
An adverse event (AE) is any untoward medical occurrence in a patient or trial subject 
administered a drug or biologic (medicinal product) or using a medical device; the event does not necessarily have a causal relationship with that treatment or usage.  
AEs include the following: 
• All suspected adverse medication reactions. 
• All reactions from medication overdose, abuse, withdrawal, sensitivity, or toxicity.  
• Apparently unrelated illnesses, including the worsening of a preexisting illness (see paragraph below on Preexisting Conditions). 
• Injury or accidents.  Note that if a medical condition is known to have caused the injury 
or accident (e.g., a fall secondary to dizziness), the medical condition (dizziness), the 
accident (e.g., fall secondary to dizziness), and any adverse outcome (e.g., hip fracture secondary to the fall) should be reported as three separate adverse events.   
• Abnormalities in physiological testing or physical examination findings that require 
clinical intervention or further investigation (beyond ordering a repeat [confirmatory] 
test).  
• Laboratory abnormalities that require clinical intervention or further investigation 
(beyond ordering a repeat [confirmatory] test) unless they are associated with an already 
reported clinical event.  Laboratory abnormalities associated with a clinical event (e.g., elevated liver enzymes in a subj ect with jaundice) should be described under Comments 
on the report of the clinical event (e.g., jaundice) rather than listed as a separate adverse event.  
Procedures  – Diagnostic and therapeutic non-invasive and invasive procedures, such as surgery, 
should not be reported as adverse events.  However, the medical condition for which the procedure was performed should be reported if it meets the definition of an AE.  For example, an acute appendicitis that begins during the adverse event reporting period should be reported as the adverse event and the resulting appendectomy noted under Comments. 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 55 of 72 
 Preexisting Conditions  – In this trial, a preexisting condition (i.e., a disorder present before the 
adverse event reporting period) should not be reported as an AE unless the condition worsens or 
episodes increase in frequency during the AE reporting period.  
Abnormal Test Findings – All laboratory test results will be reviewed by the Investigator.  The 
Investigator will utilize his/her judgment in determining if out of range laboratory values are 
clinically significant and should denote this using the abbreviation “CS” on the laboratory report 
for source documentation.  Laboratory tests that are labeled as clinically significant should be reported as AEs, either separately or as part of a description of a symptomatic AE.  If there are significant changes in a laboratory report from a previous visit that are determined to be clinically significant, these should also be reported as AEs.  Any abnormal laboratory value which requires treatment or further diagnostic testing and/or results in discontinuation from study 
should be reported as AEs. 
10.1.2  Serious Adverse Events (SAEs) 
Each adverse event is to be classified by the Investigator as SERIOUS or NONSERIOUS.  An adverse event  that meets one or more of the following criteria/outcomes is classified as serious: 
• Results in death  
• Is life -threatening (see paragraph below on Life- threatening)  
• Requires in -patient hospitalization or prolongation of existing hospitalization (see 
parag raph below on Hospitalization) 
• Results in persistent or significant disability/incapacity (see paragraph below on Disability)  
• Is a congenital anomaly/birth defect  
Important adverse events that may not result in death, be life- threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they 
may jeopardize the patient or subject or may require medical or surgical intervention to prevent one of the outcomes listed above. 
The term serious also includes any other event that the Investigator or Sponsor judges to be 
serious or which is defined as serious by the regulatory agency in the country in which the event occurred.  If there is any doubt whether the information constitutes an AE or SAE, the information is to  be treated as an SAE.  
Life-threatening – Any AE that places the subject at immediate risk of death from the event as 
it occurred.  A life-threatening event does not include an event that might have caused death had it occurred in a more severe form but that did not create an immediate risk of death as it actually occurred.  For example, drug-induced hepatitis that resolved without evidence of hepatic failure would not be considered life threatening, even though drug- induced hepatitis of a more severe 
natur e can be fatal.  
Hospitalization – Hospitalization is defined as an overnight admission with observation of a 
minimum of 24 hours.  A hospitalization planned before the start of the study for a preexisting condition that has not worsened does not constitute an SAE (e.g., elective hospitalization for a 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 56 of 72 
 total knee replacement due to a preexisting condition of osteoarthritis of the knee that has not 
worsened during the course of the study). 
Disability  – Defined as a substantial disruption in a person’s ability to conduct normal life 
functions. 
10.1.3  Severity 
The Investigator will use the adjectives MILD, MODERATE, or SEVERE to describe the 
maximum intensity of the adverse event.  For purposes of consistency, these intensity grades are defined as follows: 
MILD:  Does not interfere with subject's usual function  
MODERATE:  Interferes to some extent with subject's usual function  
SEVERE:   Interferes significantly with subject's usual function  
Note the distinction between the gravity and the intensity of an adverse event.  Severe is a measure of intensity; thus, a severe reaction is not necessarily a serious  reaction.  For example, a 
headache may be severe in intensity, but would not be classified as serious unless it met one of the criteria for serious events listed above. 
10.2 Eliciting Adverse Event Information 
The Investigator is to report all directly observed AEs and all AEs spontaneously reported by the study subject.  In addition, each study subject will be questioned about AEs at each site visit following the initiation  of treatment.  
10.3 Reporting 
Each AE is to be classified by the Investigator as SERIOUS or NONSERIOUS.  This classification of the gravity of the event determines the reporting procedures to be followed.  If an SAE occurs, expedited reporting will follow local and international regulations, as appropriate. 
All AEs that occur in study subjects during the adverse event reporting period specified in the 
protocol must be reported, WHETHER OR NOT THE EVENT IS CONSIDERED MEDICATION RELATED.  
10.3.1  Reporting Period  
The AE re porting period for this study begins from the time of informed consent and ends at the 
final protocol required visit. 
IN ADDITION, any known untoward event that occurs subsequent to the AE reporting period 
that the Investigator assesses as possibly or probably related to the study medication should also be reported as an AE.  
10.3.2  Reporting AEs  
NONSERIOUS AEs are to be reported on the adverse event case report forms.  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 57 of 72 
 10.3.3  Reporting SAEs  
Serious adverse events should be reported on both the clinical trial adverse event CRF and 
the Serious Adverse Event Report Form.  
Note:   Where the same data are collected, the forms must be completed in a consistent manner.  
For example, the same AE term s hould be used on both forms. 
Any SAE, regardless of causal relationship, must be reported to the Sponsor within 24 hours 
after the Investigator becomes aware of the SAE by completing and sending an SAE report form.  Compliance with this time requirement is  essential so that the Sponsor may comply with its 
regulatory obligations. 
The initial SAE report should be completed as fully as possible but should contain, at a minimum:  
• A description of the event and the reason why the event is categorized as serious 
• Subject identification number 
• Investigator’s name and site identification number 
• Name of the suspected medicinal product (not applicable for double-masked studies) 
• Causality assessment  
Follow-Up information relating to an SAE must be reported to the clinica l safety contact at the 
Sponsor within 24 hours of receipt by the Investigator by sending a completed SAE report form 
with new information.  The subject should be observed and monitored carefully until the condition resolves or stabilizes. 
All deaths are t o be thoroughly investigated and reported.  Autopsy reports are to be obtained, if 
possible. The Sponsor and/or its designee are responsible for reporting SAEs to all applicable regulatory 
agencies and the central ethics committees within the required timeline.  
The Investigator is responsible for submitting required safety information to their local I RB. This 
information includes but is not limited to any safety alert letter received from the Sponsor and any SAEs occurring at their site.  
10.3.4  Relationship to Study Medication  
The causal relationship of the AE to study drug will be assessed by both the Investigator and the Sponsor.  The following definitions will be used in assessment. 
Probably Related :  The AE follows a reasonable temporal sequence from the time of drug 
administration.  It follows a known response pattern to the study drug.  The AE cannot be reasonably explained by other factors such as the subject’s clinical state, therapeutic interventions, or concomitant drugs. 
Possibly Related :  The AE follows a reasonable temporal sequence from the time of drug 
administration, but could have been produced by other factors such as the subject’s clinical state, other therapeutic interventions, or concomitant drugs. 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 58 of 72 
 Unrelated :  The AE does not follow a reasonable temporal sequence from administration of the 
product or the AE is clearly related to other factors such as the subject’s clinical state, other 
therapeutic interventions, or concomitant drugs administered to the subject. 
10.3.5  Follow-Up of Unresolved Events 
All A Es should be followed until they are resolved or the Investigator assesses them as chronic 
or stable or the subject’s participation in the trial ends (i.e., until a final report is completed for that subject).  
In addition, all serious adverse events and those nonserious events assessed by the Investigator as possibly or probably related to the study medication should continue to be followed even after the subject's participation in the trial is over.  Such events should be followed until they resolve or unt il the Investigator assesses them as “chronic” or “stable.”   
10.4  Exposure In Utero  
If any study subject becomes or is found to be pregnant while receiving study medication during the treatment  period or within 30 days of discontinuing the study medication, the Investigator is 
to submit this information on a Pregnancy Notification Cover Sheet along with a completed Serious Adverse Event Form.  This must be done irrespective of whether an AE has occurred.  Pregnancy during this time frame of the female partner of a male subject should also be reported.  To ensure subject safety, each pregnancy must be reported to the Sponsor’s Medical Monitor or CRO designee within 24 hours of awareness of the pregnancy.  
If the pregnancy of a female study participant is discovered during the study , study medication 
should be discontinued. The Investigator will follow the subject (or female partner of a male subject) until completion of 
the pregnancy and will follo w the neonate up to 1 month of birth. 
Within 24 hours of awareness, Investigator sites will notify the Sponsor’s Medical Monitor or CRO designee of abnormal pregnancy outcomes.  Normal outcomes may be reported within 5 
days of awareness .  Reporting of outcome will be provided on the Pregnancy Reporting Form. 
In addition to reporting the outcome on the Pregnancy Reporting Form, if the outcome of the pregnancy meets the criteria for immediate classification as a SAE (i.e., spontaneous abortion, stillbirth , neonatal death within one month of birth, or congenital anomaly [including that in an 
aborted fetus]), the Investigator should also follow the procedures for reporting a SAE within 24 hours of awareness.  
Additional information about pregnancy outcomes follows: 
• Note that “spontaneous abortion” includes miscarriage and missed abortion. 
• All neonatal deaths that occur within one month of birth should be reported, without 
regard to causality, as SAEs.  In addition, any infant death after one month that the 
Investigator assesses as possibly or probably related to the in utero exposure to the study 
medication should also be reported. 
• In the case of a live birth, the “normality” of the newborn can be assessed at time of birth. 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 59 of 72 
 • The “normality” of an aborted fetus c an be assessed by gross visual inspection unless 
there are pre-abortion laboratory findings suggestive of a congenital anomaly. 
11 DATA ANALYSIS  
11.1 Sample Size Determination 
Estimates for sample size calculations are derived from published data from the analysis  of the 
effect of ranibizumab (Lucentis) and aflibercept (Eylea) intravitreal administration regimens on 
DR severity score in the RISE/ RIDE studies and VIVID/VISTA studies, respectively, in which at least 28 -46% of subjects improved by ≥ 2 steps after 12 months of treatment.  
With 45 evaluable subjects per treatment group, the study has >85% power (based on Fisher’s 
Exact Test and a 2 -sided alpha =0.05) to demonstrate a statistically significant improvement in 
percent of subjects improving by ≥ 2 steps on t he ETDRS severity scale, assuming underlying 
rates for active and placebo of 30% and 5%, respectively.  Assuming 10% drop-out/non-
evaluable rate, a sample size of 50 subjects per  treatment arm (approximately 1 50 total) has been 
selected.  
11.2 Study Populations 
11.2.1  Safety Populations 
The safety population will include all enrolled subjects who receive at least one (1) dose of study medication.  All safety analyses will be conducted using the safety population. 
11.2.2  Efficacy Populations 
 Modified Intent -to-Treat Population  
The modified intent- to-treat (MITT) population will include all enrolled subjects who receive at 
least one dose of study medicatio n. The primary efficacy analysis will be conducted using the 
MITT population. 
 Per Protocol Population 
The per protocol (PP) population will consist of all subjects in the MITT population who do not 
have major protocol deviations considered to affect the primary efficacy variable DRSS , have 
completed a minimum of 12 months of treatment  and have been at least 70% compliant.  
Sensit ivity analyses of the primary efficacy variables will be conducted using the PP population. 
11.3 Analysis of Demographics and Baseline Variables 
Descriptive statistics (e.g., number of subjects, mean, standard deviation (SD), median, minimum, and maximum) will be generated for selected continuous variables (age, selected 
laboratory assays, vital signs, etc.) for each treatment group and for all subjects.  The number and percentage of subjects in each class of categorical demographic and baseline variables (e.g.,  
ethnicity, and race) will be tabulated for each treatment group and for all subjects.  Individual subject demographic and baseline characteristic data will be listed.  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 60 of 72 
 11.4 Disposition of Subjects 
The number and percentage of subjects who are enrolled, complete the study, discontinue study 
medication, or withdraw from the study including reasons for study medication discontinuation or study withdrawal will be summarized along with the number and percentage of subjects in each of the analysis populations (safety,  MITT, and PP) in tabular format by treatment group and 
for all subjects.  Individual subject disposition data will be listed.  
11.5 Study Days and Assessment Windows  
Study days will be numbered relative to the first day of dosing.  The start of study (Day  1) will 
be defined as the date on which a subject takes the first dose of any study medication, as 
recorded on the CRF.  Relative to study start, days will be numbered …-2, -1, 1, 2, ... with Day -1 being the day prior to the start of study medication (Pre- Dose).   
Recorded data will be assigned to evaluation/assessment windows.  If more than one clinical evaluation is made within a window for a particular visit, the record with the worst assessment will be used for the assessment in that window. 
11.6 Safety Analysis 
All subjects who receive at least one dose of any study medication will be included in the safety analysis.  All safety endpoints are listed in Section 5.6.3. 
All AEs reported during the study period will be recorded and coded using MedDRA 
terminology.  An AE will be considered as treatment- emergent if it has an onset during the 
treatment period or is pre-existing and worsens after the first dose of study medication is 
administered.  The incidence of all reported treatment -emergent adverse events (TEAEs) will be 
summarized using system organ class and preferred term by treatment group and overall, using counts and percentages.  Separate analyses will be performed for ocular and non-ocular TEAEs.  These summaries will also be provided for treatment related TEAEs and TEAEs by severity.  For ocular TEAEs, the subject will be considered to have had the TEAE if at least one eye had the TEAE.  
Continuous safety endpoints collected at each visit will be summarized with number of subjects, mean, standard deviation (SD), median, minimum, and maximum for each treatment group and for all subjects.  Qualitative variables collected at each visit will be summarized using counts and percentages for each treatment group and for all subjects.  Summaries will also include change from baseline and shift tables, where appropriate.  Individual subject safety data will be l isted.  
11.7 Efficacy Analyses 
All efficacy endpoints are listed in Section s 5.5 and 5.6. All  efficacy data will be summarized by 
treatment group and time point usi ng appropriate descriptive statistics. Summaries will be 
presented for both the MITT and PP populations. Due to the small number of subjects that are expected to be enrolled at each center, all summaries and analyses will be performed using data pooled acr oss centers.  
The primary hypotheses to be tested is that AKB-9778 15mg twice daily and AKB-9778 15mg once daily will be superior to placebo in the improvement of DR as measured by the ETDRS severity scale change from baseline at 12 months. Specifically, t he primary endpoint is the 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 61 of 72 
 percentage of subjects with an improvement in study eye severity of DR  (ETDRS  DR Severity 
Score or DRSS) of ≥ 2 steps at Month 12 without need for treatment of PDR or DME (by IVT, 
laser, or vitrectomy) in the study eye.  The primary hypotheses will be tested in the MITT population using a Fisher’s Exact Test with a 2-sided 5% significance level.  To adjust for multiplicity, a pre -specified testing order will be used.  AKB-9778 15mg twice daily will be 
tested first, and A KB-9778 15mg once daily will be tested second.  Details of how missing data 
will be handled for the primary endpoint, along with sensitivity analyses to assess the impact of missing data will be outlined in the statistical analysis plan (SAP).  
Secondary an d exploratory endpoints will be analyzed without adjustment for multiplicity, and 
all inferential analyses will use a 2 -sided 5% significance level.  Continuous variables will be 
analyzed using ANCOVA models and/or repeated measures mixed effect models and  
dichotomous variables will be analyzed using the same approach as outlined for the primary endpoint.  Details of how missing data will be handled for secondary and exploratory endpoints will be provided in the SAP.   
Exploratory analyses will be conducted to understand the relationship between exposure and 
response and details of these analyses will be outlined in the SAP.
 
11.8 Pharmacokinetic Analyses   
AKB -9778 plasma concentrations will be summarized by treatment group and nominal sampling 
time using descriptive statistics.  Individual subject pharmacokinetic data will be listed.  
Additional analyses including the potential relationship of plasma concentration and selected safety and efficacy parameters and/or subject demographic variables will be performed. 
11.9 Pharmacodynamic Analyses   
Blood samples collected at baseline and Month 12 End of Treatment (EOT) will be retained for exploratory analysis of biomarkers in plasma.  Once results of the study are known, the Sponsor will determine the value of conducting th ese analyses.  
11.10   Exploratory Genetic Analyses   
For subjects who have provided consent for genetic sampling, a blood sample will be retained for exploratory genetic analysis that may provide insight into the role of Tie2 in diabetic retinopathy and an individual subject's response to AKB-9778 treatment.  Once results of the study are known, the Sponsor will determine the value of conducting these analyses. 
12 DATA HANDLING AND RECORD KEEPING  
12.1 Case Report Forms (CRFs) 
Case Report Forms (CRFs) are required and should be completed for each included subject.  The 
completed original CRFs are the sole property of the Sponsor and should not be made available in any form to third parties, except for authorized representatives of the Sponsor or appropriate regulatory authorities, without written permission from the Sponsor.  CRFs for this study will be electronic (eCRFs).  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 62 of 72 
 The Investigator has ultimate responsibility for the accuracy, authenticity, and timely collection 
and reporting of all clinical, safety, and laboratory data entered on the CRFs and any other data collection forms.  The CRFs must be signed by the Investigator (for electronic CRFs, they can be signed electronically ) to attest that the data contained on the CRFs is true.  Any corrections to 
entries made i n the CRFs and source documents must be dated, initialed and explained (if 
necessary) and should not obscure the original entry.  
In most cases, the source documents are contained in the subject’s chart at the hospital or the 
physician's office.  In these cases, data collected on the CRFs must match the data in those charts.  
12.2 Record Retention 
To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator agrees to keep records, including the identity of all participating subjects (sufficient information to link records, e.g., CRFs and hospital records), all original signed Informed Consent Forms, copies of all CRFs, SAE forms, source documents, detailed records of drug disposition, and adequate documentation of relevant corr espondence (e.g., letters, meeting minutes, telephone 
calls reports).  The records should be retained by the Investigator according to the International Conference on Harmonisation (ICH), local regulations, or as specified in the Clinical Study Agreement, whichever time period is longer. 
If the Investigator becomes unable for any reason to continue to retain study records for the required period (e.g., retirement, relocation), the Sponsor should be prospectively notified.  The study records must be transferred to a designee acceptable to the Sponsor, such as another Investigator, another institution, or to the Sponsor.  The Investigator must obtain Sponsor’s written permission before disposing of any records, even if retention requirements have been met. 
13 QUALITY CONTROL (QC) AN D QUALITY ASSURANCE (QA) 
13.1 Study Site Monitoring Visits 
During study conduct, the Sponsor or its agent will conduct periodic monitoring visits to ensure that the protocol, Good Clinical Practice (GCP), and applicable local regulations are being followed.  The monitors will review source documents to confirm that the data recorded on CRFs is accurate.  The Investigator/institution will allow Sponsor monitors or designees and appropriate regulatory authorities direct access to source documen ts to perform this verification.  
The study site may also be subject to QA audits and Regulatory Inspections performed by the Sponsor or companies working with or on behalf of the Sponsor, and/or review by the IRB, and/or to inspection by appropriate regulatory authorities 
It is important that the Investigator and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 63 of 72 
 13.2 Protocol Deviations 
The Investigator shoul d not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to study subjects.  Should other unexpected circumstances arise that will 
require deviation from protocol-specified procedures, the Investigator should consult with the Sponsor or designee (and IRB, as required) to determine the appropriate course of action. 
The site should document all protocol deviations in the subject’s source documents.  In the event 
of a significant deviation, the site should notify the Sponsor or its designee (and IRB, as required) immediately.  Significant deviations include, but are not limited to, those that involve fraud or misconduct, increase the health risk to the subject, or confound interpretation of primary study assessments.  
14 TRIAL DISCONTINUATION/INVESTIGAT IVE SITE TERMINATION  
The Sponsor reserves the right to discontinue the study prior to inclusion of the intended number of subjects, but intends only to exercise this right for valid scientific or administrative reasons.  After such a decision, the Investigator must contact all participating subjects within a time period specified by the Sponsor to inform them of the decision to discontinue the trial.   
The study may also be put on hold or discontinued by IRB or Regulatory Authority. 
14.1 Criteria for Premature Termination or Suspension of the Study 
The following criteria may result in either temporary suspension or early termination of the 
study:  
• New information regarding the safety or efficacy of the study medication that indicates a change i n the known risk/benefit profile for the compound, such that the risk/benefit is no 
longer acceptable for subjects participating in the study.  
• Significant violation of GCP that compromises the ability to achieve the primary study 
objectives or compromises subject safety.  
The Sponsor reserves the right to discontinue the trial for other valid administrative reasons. 
14.2 Criteria for Premature Termination or Suspension of Investigational Sites 
A study site may be terminated prematurely or suspended if the site (including the Investigator) 
is found to be in significant violation of GCP, protocol, contractual agreement, or is unable to ensure adequate performance of the study or guarantee safety of participating subjects.  
14.3 Procedures for Premature Termination or Suspension of the Study or 
Investigational Site(s)  
In the event that the Sponsor elects to terminate or suspend the study or the participation of an 
Investigational site, a study -specific procedure for early termination or suspension will be 
provided by the Sponsor; the procedure will be followed by applicable Investigational sites during the course of termination or study suspension. 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 64 of 72 
 15 ETHICS 
15.1 Ethical Conduct of the Study 
The study will be conducted in accordance with the Declaration of Helsinki on Ethical Principles 
for Medical Research Involving Human Subjects, adopted by the General Assembly of the World Medical Association (1996). 
In addition, the study will be conducted in accordance with the protocol, the ICH guideline on 
GCP, and applicable local regulatory requirements and laws.  
15.2 Institutional Review Board (IRB)  
It is the responsibility of the Investigator to have prospective approval of the study protocol, protocol amendments, informed consent forms, and other relevant documents, (e.g., recruitment advertisements, if applicable) from the IRB prior to implementation.  All correspondence with 
the IRB should be retained in the Investigator File.  Copies of IRB approvals should be forwarded to the Sponsor. 
The only circumstance in which an amendment may be initiated prior to IRB approval is where 
the change is necessary to eliminate apparent immediate hazards to the subjects.  In that event, the Investigator must notify the IRB and the Sponsor in writing immediately after the implementation.  
15.3 Subject Information and Consent  
It is the responsibility of the Investigator, or a person designated by the Investigator, to give each subject (or the subject’s acceptable representative), prior to inclusion in the study, potential benefits of participation, and the possible risks involved.  The Investigator should ensure all questions the subject may have regarding participation are answered.  The process must be conducted in a language understood by the subject.  The subject must be informed about their right to withdraw from the trial at any time without consequence.   
Furthermore, it is the responsibility of the Investigator, or a person designated by the Investigator, to obtain a freely signed informed consent from each subject or the subject’s legally acceptable rep resentative prior to inclusion in the trial.  The Investigator will retain the original 
of each subject's signed consent form.  The subject (or the subject’s acceptable representative) must be provided a copy of the signed form. 
The informed consent form must be in compliance with ICH GCP, local regulatory requirements, 
and legal requirements.  The informed consent form used in this study, and any changes made during the course of the study, must be prospectively approved by both the IRB and the Sponsor before use. The Investigator must re consent subjects on updated material as required by the IRB 
and local regulatory, and legal requirements. 
15.4 Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP 
In the event of any prohibition or restriction imposed (i.e., clinical hold) by an applicable Competent Authority, or if the Investigator is aware of any new information which might influence the evaluation of the benefits and risks of the investigational product, the Sponsor should be informed i mmediately.  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 65 of 72 
 In addition, the Investigator will inform the Sponsor immediately of any urgent safety measures 
taken by the Investigator to protect the study subjects against any immediate hazard, and of any serious breaches of this protocol or of ICH GCP that comes to the attention of the Investigator. 
15.5 Subject Confidentiality 
All parties will ensure protection of subject personal data and will not include subject names on any Sponsor forms, reports, publications, or in any other disclosures, except where required by laws.  In case of data transfer, the Sponsor will maintain high standards of confidentiality and protection of subject personal data. 
The Sponsor and designees affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy.  Throughout this study, a subject’s source data will only be linked to the Sponsor’s clinical study database or documentation via a unique identification number.  As permitted by all applicable laws and regulations, limited subject attributes, s uch as sex, age, or 
date of birth, and subject initials may be used to verify the subject and accuracy of the subject’s unique identification number. 
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the 
Sponsor requires the Investigator to permit its monitor or designee’s monitor, representatives from any regulatory authority (e.g., FDA), the Sponsor’s designated auditors, and the appropriate IRB to review the subject’s original medical records (source data or documents), including, but not limited to, laboratory test result reports, ECG reports, admission and discharge summaries for hospital admissions occurring during a subject’s study participation, and autopsy reports.  Access to a subject’s original medical records requ ires the specific authorization of the subject as part of 
the informed consent process. 
Copies of any subject source documents that are provided to the Sponsor must have certain 
personally identifiable information removed (i.e., subject name, address, and other identifier fields not collected on the subject’s CRF). 
16 PUBLICATION OF STUDY RESULTS 
No publication or disclosure of study results will be permitted, except under the terms and conditions of a separate, written agreement between Sponsor and the Investigator and/or the Investigator’s institution.  The Sponsor must have the opportunity to review and approve all proposed abstracts, manuscripts, or presentations regarding this study prior to submission for publication/presentation.  Any information identified by the Sponsor as confidential must be deleted prior to submission. 
For all publications relating to the study, the institution will comply with recognized ethical 
standards concerning publications and authorship, including:  Section II - “Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, established by the International Committee of Medical Journal Editors.  
 
  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 66 of 72 
 17 REFERENCES  
Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and 
homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009 
Mar;10(3):165-77. 
Barber MD, Abraham A, Brydon WG, et al. Assessment of faecal occult blood loss by 
qualitative and quantitative methods. J R Coll Surg Edinb. 2002 Apr;47(2):491-4.  
Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular 
protection. Circ Res. 2006 April 28; 98(8): 1014–1023. 
Campochiaro PA, Khanani A, Singer M, et al; Enhanced benefit in diabetic macular edema from 
AKB -9778 Tie2 activation combined with vascular endothelial growth factor suppression. 
Ophthalmology. 2016 Aug;123(8):1722-30 
Campochiaro PA, Sophie R, Tolentino M, et al. Treatme nt of diabetic macular edema with an 
inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology. 2015 Mar;122(3):545-54. 
Davis JS, Yeo TW, Piera KA, Woodberry T, Celermajer DS, Stephens DP, et al. Angiopoietin-2 
is increased in sepsis and inversely associated with nitric oxide- dependent microvascular 
reactivity. Crit Care. 2010;14(3):R89. Epub 2010 May 18. 
Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high- risk proliferative diabetic 
retinopathy and severe v isual loss: Early Treatment Diabetic Retinopathy Study Report 
#18. Invest Ophthalmol Vis Sci. 1998 Feb;39(2):233-52. 
Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends 
Immunol. 2006 Dec;27(12):552-8. Epub 2006 Oct 12.  
Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27:2540-
53.  
Fong DS, Aiello L, Gardner TW, et al; American Diabetes Association. Retinopathy in diabetes. 
Diabetes Care. 2004;27 Suppl 1:S84-7. 
Guariguata L, Whiting DR, Hambleton I,  Beagley J, Linnenkamp U, Shaw JE. IDF Diabetes 
Atlas: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research and Clinical Practice. 2014 .  
Harewood GC, McConnell JP, Harrington JJ, et al. Detection of occult upper gastrointestinal 
tract bleeding: performance differences in fecal occult blood tests. Mayo Clin Proc. 2002 Jan;77(1):23-8. 
Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on 
diabetic retinopathy severity and progression. Arch Ophthalmol. 2012 Sep;130(9):1145-52. 
Klein R, Klein BE, Moss SE. How many steps of progression of diabetic retinopath y are 
meaningful? The Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2001 Apr;119:547-53. 
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 67 of 72 
 Klein R, Knudtson MD, Lee KE,  Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of 
Diabetic Retinopathy: XXII the twenty -five-year progr ession of retinopathy in persons 
with type 1 diabetes. Ophthalmology, 2008. 115(11): p. 1859-68. 
Klein R, Knudtson MD, Lee KE,  Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of 
Diabetic Retinopathy XXIII: the twenty -five-year incidence of macular edema in persons 
with type 1 diabetes. Ophthalmology, 2009. 116(3): p. 497-503. 
Korobelnik JF, Do DV, Schmidt- Erfurth U, Boyer DS, et al. Intravitreal aflibercept for diabetic 
macular edema. Op hthalmology. 2014 Nov;121:2247-54. 
Llanos L, Moreu R, Ortin T, P eiro A, Pascual S, et al. Existence of a relationship between 
increased serum alanine aminotransferase levels (ALT) detected in premarketing clinical 
trials and postmarketing published hepatotoxicity case- reports. Alimentary Pharmacology 
and Therapeutics, Wiley, 2010, 31 (12), pp.1337. 
Maa AY, Feuer WJ, Davis CQ, Pillow EK, et al. A novel device for accurate and efficient testing 
for vision-threatening diabetic retinopathy. J Diabetes Complications. 2016;30(3):524-32. 
Milner CS, Hansen TM, Singh H, Brindle NP. Roles of the receptor tyrosine kinases Tie1 and 
Tie2 in mediating the effects of angiopoietin -1 on endothelial permeability and apoptosis. 
Microvasc Res. 2009 Mar;77(2):187-91. Epub 2008 Sep 20. 
Peters KG, Kontos CD, Lin PC, Wong AL, Rao P, Huang L, et al. Functional significance of 
Tie2 signaling in the adult vasculature. Recent Prog Horm Res. 2004;59:51-71. 
Rockey DC, Auslander A, Geenberg PD. Detection of upper g astrointestinal blood w ith fecal 
occult  blood t ests.  Am J Gastroenterology. 1999. Vol. 94(2): 344-350.  
Shen J, Frye M, Lee BL, et al. Targeting VE- PTP activates TIE2 and stabilizes the ocular 
vasculature. J Clin Invest 2014; 124:4564-76. 
Yau JW, Rogers SL, Kawasaki R, et al. Meta -Analysis for Eye Disease (META -EYE) Study 
Group. Global preval ence and major risk factors of diabetic retinopathy. Diabetes Care. 
2012;35:556-64. 
  
Protocol No. AKB -9778- CI-5001   18September2017  
Amendment #5 Integrated    
 
 
Aerpio  — Company Confidential  
Page 68 of 72 
 18 APPENDICES    
18.1 Appendix A : Schedule of Activities  
   
 
 
Protocol No. AKB -9778- CI5001   18September2017  
Amendment # 5 Integrated    
Aerpio  — Company Confidential  
Page 69 of 72  
Schedule of Activities [A]  
Protocol Activities  Screening  Baseline  Treatment  Period [B]  F/U 
Day Month   
Day - 28 to  
Day - 1 Day 1 
Pre-Dose  Day 1  Day 7 M1 M2 M3 M4 M5 M6 M7 M8 M9 M10  M11  M12 
(EOT)  EOT + 
1M 
                  
Informed Consent  X                 
Eligibility Criteria  X                 
Demograph ics X                 
Medi cal/Ophthalmic History  X X               X 
Height We ight and Temperature [C]  X         X      X  
Body Sy stem Assessments [D]   X      X   X   X   X X 
ECG [E]  X         X      X  
                   
Vitals [F ]                  
  Sitting BP and HR  X X X  X X X  X X X X X X X X X  
                   
Eye and Vision Exams                   
   ETDRS BCVA  X X   X X X X X X X X X X X X  
   Slit Lamp Biomicroscopy  X X     X   X   X   X  
   Intraocular Pressure   X X     X   X   X   X  
   Dilated Indirect Ophthalmoscopy  X X     X   X   X   X  
   SD OCT  X      X   X   X   X  
   Fundus Photography [G] X      X   X   X   X  
   Fluore scein Angiography [H] X         X      X  
   OCT Angiography Sub Study [ I]    X     X   X   X   X  
   ERG Sub Study [ I]  X     X   X   X   X  
                  
                   
Labo ratory Procedures                   
   Serum/ Urine Pregnancy [ J] X X        X      X  
   Hematology [K] X  X    X  X  X  X  X  X  
   Chemistry  [L] X X   X X X X X X X X X X X X  
   Urinalysis  [M]  X        X   X   X  
   Fecal Occult Blood Test  [N] X         X   X   X  
   Biomarker Blood Sampling   X              X  
   Blood sampling for Genetic Analyses   X                
   PK Blood Sampling [ O]   X       X        
                  
   Dosing [ P]    X X X X X X X X X X X X X X  
   Study medication dispensing & return, 
diary review [ Q]   X  X X X X X X X X X X X X  
                     
AE collection [ R] [S] X X X X X X X X X X X X X X X X X 
Concomita nt Medication Review [ T] X X X X X X X X X X X X X X X X  
[A] Assessments are conducted at the study site unless otherwise noted.   
Protocol No. AKB -9778- CI5001   18September2017  
Amendment # 5 Integrated    
Aerpio  — Company Confidential  
Page 70 of 72 [B] Site visits scheduled for Months 1 through 12 should be conducted within 28 days times the study month number ±3 days relativ e to the baseline visit . Homecare nurse visits scheduled 
for Screening, Months 3, 6, 9 and 12 should  be conducted within 1 week after the corresponding site visit.  The Follow -up homecare nurse visit is to be conducted 4 weeks (± 3 days) after 
the EOT visit at the investigative site.  
[C] Height is collected at screening only.  
[D] Body system assessments are conducted at the home care nursing visit.  
[E] ECGs will be performed after the subject rests in a supine position for approximately 5 minutes.  ECGs should be taken prior to any vital sign assessments or bloo d draws.  
[F] Assessments are conducted prior to any blood draws when possible. On Day 1, sitting BP and HR assessments will be conduct ed at Baseline (pre-dose) and at 30 and 90 minutes post -
dose.  On the Month 6 visit, sitting BP and HR assessments will b e conducted prior to administration of the AM dose at the site and at 30 and 90 minutes after the AM dose.  
[G] For sites participating in the UWF imaging sub study, at the Screening, Month 6 and Month 12 (EOT) vists, UWF fundus photogra phs will be obtaine d in addition to standard fundus 
photographs.  
[H] For sites participating in the UWF imaging sub -study, UWF FA will be performed in lieu of FA.  
[I] Performed only at sites with required equipment available.  
[J] In women of child bearing potential, a serum  pregnancy test will be conducted at the Screening visit . Prior to dosing on Day 1, a urine pregnancy test will be conducted on Day 1. At the 
Month 6 and Month 12 site visits , a urine pregnancy test will be conducted.  
[K] HbA1C is conducted at Screening, Baseline, Month 6 , and Month 12.  
[L] eGFR will be determined on serum chemistry samples collected at the Screening, Baseline, Month 6, Month 9, and Month 12 (EOT)  visits.  
[M] UACR is measured at  Baseline, Month 6, Month 9, and Month 12 (EOT) visits; subjects should refrain from heavy exercise 24 hours before these visi ts. 
[N] Sites will distribute instructions and materials to subjects for home specimen collection and shipping to the central laboratory. Subjects will collect their specimens and are responsible for 
shipping to the clinical laboratory for testing; specimen collection and shipping should be conducted within one week following the site visit. Homecare nurses will review status of spec imen 
collection and shipping with subjects.  
[O] Subjects are to be instructed prior to the Month 6 visit to NOT take the AM dose prior to their visit and to bring their AM dose to the visit along with other study medication in kits, as the 
AM dose will be administered in the clinic on this visit. The post -dose PK sample collection on Day 1 and Month 6 is relative to time of dose administration. PK blood sampling is conducted 
at 30 and 90 minutes after dosing ± 10 minutes. PK blood samples are to be collecte d after vital signs are conducted.  
[P] On Day 1 and Month 6, subjects will administer  their AM dose at the site.  Prior to dosing on these visits, subjects should eat a snack or meal and drink 1- 2 glasses of fluid.  Subjects will 
self-dose in the seated p osition and remain seated for 30 mins. Subjects will dose BID with the exception of Day 1 when the subject will dose the AM dose at the site and will begin the BID 
dosing schedule on Day 2.   
[Q] At Baseline, subjects will be trained on administration of s tudy medication. Subjects will be provided with a dosing diary and dosing supplies at Day 1, and monthly during the treatment  
period.  
[R] All adverse events (serious and non -serious, and related and non-related) will be documented and recorded through the last protocol specified visit.   
[S] If the home healthcare nurse identifies any potential AEs during the home visit, the nurse will communicate directly to the study site and the Investigator will be responsible for 
determination of AEs and any necessary follow -up with the subject  
[T] All concomitant medications received up to and including 28 days prior to the start of study medication through the Month 12 visit will be recorded.  
 
Protocol No. AKB -9778- CI5001   18September2017  
Amendment # 5 Integra ted   
Aerpio  — Company Confidential  
Page 71 of 72 18.2  Appendix B: Criteria for Treatment of PDR or DME in the Study Eye or 
Qualified Fellow Eye During the Study 
Standardizing the criteria to treat PDR or DME during this study will allow for enhanced 
evaluation of the effect of AKB-9778 monotherapy on diabetic retinopathy . These criteria have 
been adapted from the DRCR.net Protocol W (http://drcrnet.jaeb.org/Studies.aspx?RecID=340 ).  
If a study eye or qualified fellow eye treated for PDR or DME, study medication may be 
discontinued at the discretion of the Investigator and subject . If a non-qualified fellow eye 
requires treatment for PDR or DME, the subject will remain in the study.  
o Criteria for treatment of PDR or DME in the study eye or qualified fellow eye and 
allowed treatments are presented below. Non- qualified  fellow eyes may be treated 
at the discretion of the Investigator.  
o Refer to Section 8.4.3 for additional details regarding assessments to be conducted 
prior to treatment of PDR or DME.  
 Treatment for PDR  in the study eye or qualified fellow eye should not be given unless at least 
one of the following is present: 
1. Neovascularization of the angle or neovascular glaucoma  
2. Neovascularization of the disc (NVD) greater than standard photograph 10A (1/4 to 1/3 disc area)  
3. Any NVD with pre-retinal or vitreous hemorrhage  
4. Neovascularization elsewhere ( NVE ) greater than ½ disc area with pre-retinal or vitreous 
hemorrhage 
5. Vitreous hemorrhage (VH) requiring treatment that is presumed to be from PDR  
6. If none of the above is met, Reading Center confirmation of neovascularization within the 
7-field fundus photo area should be obtained prior to initiating treatment whenever possible 
Treatment of neovascularization outside of the 7-field fundus photo area without the presence of pre-retinal or vitreous hemorrhage is discouraged ( If the 
Investigator believes treatment for peripheral neovascularization is necessary, the 
sponsor should be informed prior to initiation).  
Treatment for PDR can include:  
1. Anti-VEGF IVT  
2. PRP / sector Laser photocoagulation 
3. Vitrectomy  
 Treatment for DME in the study eye or qualified fellow eye should not be given unless t here is 
center -involved DME on clinical exam with ≥ 10% increase in CST from baseline and : 
1. ≥ 10 letter loss of BC VA at a single visit or 
2. 5 to 9 letter loss of BC VA at 2 consecutive visits 
Protocol No. AKB -9778- CI5001   18September2017  
Amendment # 5 Integra ted   
Aerpio  — Company Confidential  
Page 72 of 72 Treatment for DME can include:  
1. Anti-VEGF or steroid IVT  
2. Grid / focal Laser photocoagulation 